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Abstract 
 
This study was designed to retrospectively evaluate the established embryo vitrification/warming programme 
currently implemented at Drs Aevitas Institute for Reproductive Medicine and to look at factors that might play 
a role in optimizing the pregnancy outcomes thereof.  
Vitrification is the achievement of a “state of suspended animation” wherein molecular translational motions are 
arrested without structural reorganization of the liquid. In embryo vitrification it involves placement of the 
embryo in a very small volume of vitrification medium that must be cooled at extremely high cooling rates. The 
vitrification medium contains cryoprotectants to prevent any cryoinjury from occurring to the embryo. 
This process was initially proposed to effectively manage supernumerary embryos, but it has also provided a 
viable method of reducing costs for additional embryo transfers as well as the reduction of the incidence of 
multiple births. Patients who are at risk of ovarian hyper stimulation syndrome (OHSS) can also have all of their 
embryos vitrified in advance to reduce the likelihood of adverse clinical symptoms if a pregnancy is established. 
Throughout the period in which vitrification has been in practice, there have been advances in technology as 
well as continual research being conducted to establish whether newly suggested techniques do, in fact, optimize 
the outcomes of vitrification. Focus has subsequently been applied to the carrier device used for vitrification, the 
day on which the embryos are vitrified and stored, as well as the number of embryos transferred in each 
respective cycle, all to ensure the most favourable outcome.  
This retrospective study confirmed the use of the Cryotop® as the most viable carrier device for successful 
survival and pregnancy outcomes. Transfer of day 5 vitrified embryos resulted in significantly higher pregnancy 
rates compared to day 6 vitrified embryos. Results also indicated that the number of embryos transferred does 
indeed have a significant effect on the pregnancy outcome and consequently we can possibly argue against the 
implementation of single embryo transfer in the vitrification programme. Investigation into the effect of female 
age, specifically oocyte age, on each of these categories indicated that reduced age can be associated with 
optimal outcomes; however this could not be proven statistically in this cohort of patients. 
To further look at optimization of the vitrification/warming programme, a Literature Survey was conducted to 
ascertain the results after Assisted Hatching in frozen/warmed human embryos. Assisted Hatching has been 
proposed as a solution to Zona Pellucida hardening, which has been found to occur during vitrification. The 
need for further studies and a meta-analysis of the literature is confidently proposed, as well as a Prospective 
Study to evaluate the effect of Laser Assisted Hatching in the human blastocyst vitrification/warming 
programme at Drs Aevitas Institute for Reproductive Medicine. 
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Opsomming 
 
Hierdie studie is ontwerp om die gevestigde embrio vitrifikasie/ontdooi program by Drs Aevitas Instituut vir 
Reproduktiewe Medisyne, retrospektief te evalueer en die faktore te optimaliseer wat swangerskap uitkomste 
kan beïnvloed.  
Vitrifikasie is die proses waardeur die molekulere aktiwiteit binne die embrio in ‘n staat van arres gehou word 
sonder om die strukture binne die sitplasma te versteur. Dit behels die plasing van ŉ embrio in 'n klein 
hoeveelheid vitrifikasie medium wat teen 'n hoë tempo afgekoel word. Die vitrifikasie medium bevat 
kriobeskermmiddels wat die embrio tydens die vitrifikasie proses teen moontlike skade beskerm.  
Hierdie proses is aanvanklik voorgestel om oortollige embrio’s doeltreffend te bestuur. Dit bied ŉ koste 
effektiewe metode vir embrio terugplasing, en verlaag die insidensie van veelvoudige swangerskap. Vitrifikasie 
bied pasiënte met ŉ hoë risiko vir ovariale hiperstimulasiesindroom (OHSS) ‘n alternatief om nadelige kliniese 
simptome te vermy indien ŉ swangerskap bereik word.  
Tegnologiese vordering en voortdurende navorsing ondersoek voortdurend nuwe tegnieke vitrifikasie uitkomste 
te optimaliseer. Fokus word geplaas op die draertoestel wat gebruik word vir vitrifikasie, die dag waarop die 
embrio's gevitrifiseer en gestoor word, sowel as die aantal embrio’s wat met elke vitrifikasie siklus teruggeplaas 
word.  
Hierdie retrospektiewe studie het bevestig dat die gebruik van die Cryotop® die mees suksesvolle toestel vir 
oorlewing en swangerskap uitkomste is. Die terugplasing van dag 5 gevitrifiseerde embrios het beduidende hoër 
swangerskapsyfers as dag 6 embrios tot gevolg gehad. Die resultate het ook aangedui dat die aantal embrio's wat 
teruggeplaas word 'n beduidende uitwerking op die swangerskapsyfer het. Daar kan dus moontlik teen die 
implementering van 'n enkel embrio-terugplasing neiging in die vitrifikasie program geargumenteer word. 
Resultate het ook getoon dat optimale uitkomste verwant is aan ŉ laer oösiet ouderdom, alhoewel dit nie in die 
groep pasiente statisties bewys kon word nie. 
'n Literatuurstudie oor AH (Assisted Hatching) op gevitrifiseerde/ontdooide menslike embrio’s is uitgevoer om 
die vitrifikasie/ontdooi program verder te optimaliseer. AH bied ‘n oplossing vir Zona pellucida verharding, wat 
tydens vitrifikasie plaasvind. Verdere studies, 'n meta-analise van die literatuur, sowel as 'n prospektiewe studie 
om die effek van laser AH in gevitrifiseerde/ontdooide menslike blastosiste by Drs Aevitas Instituut vir 
reproduktiewe medisyne te evalueer, word voorgestel.  
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1.1. Short History of Assisted Reproductive Technology [ART] 
 
The history of ART and embryo transfer (ET) dates back to as early as 1890. Walter Heape, a 
professor and physician at the University of Cambridge, England, who had been conducting 
research on reproduction in a number of animal species, reported the first known case of 
embryo transplantation in rabbits. This was long before the applications to human fertility 
were even suggested. 
However, it was not until 1959 that indisputable evidence of in vitro fertilization (IVF) was 
obtained by Chang (Chang, 1959) who was the first to achieve births in a mammal (a rabbit) 
by IVF. The newly-ovulated oocytes were fertilized, in vitro by incubation with capacitated 
sperm cells in a small Carrel flask for 4 hours, thus opening the way to assisted procreation. 
1978 marked the first ever human IVF birth (Louise Brown), which occurred in Oldham, 
England on July 25. This birth was the result of the collaborative work of Patrick Steptoe and 
Robert Edwards (Steptoe and Edwards, 1978). Robert Edwards received the Nobel Prize for 
Physiology and Medicine in 2010 for this development of IVF and ET to treat infertility in 
women with non-patent oviducts. (Biggers, 2005).  IVF and  ET involves four main aspects: 
i) the acquisition of viable, mature oocytes ii) the fertilization of these mature oocytes in vitro 
iii) the culture of the fertilized and thus preimplantation embryos and iv) the transfer of the 
embryos into the uterus of the mother (Biggers, 2012). Ultimately human IVF and ET were 
built upon extensive research produced by many investigators for over a century (Biggers, 
2012).  Robert Edwards was able to build on his earlier work and that of his colleagues, and 
in turn he was able to make major scientific contributions in the field of Reproductive 
Biology.  Today there are accounts of over 4 million IVF/ET births worldwide (Biggers, 
2012). 
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1.2. Multiple Gestations in ART 
 
With the refinement of extended culture systems (Kader et al. 2009), the occurrence of full 
term IVF pregnancies, and thus live birth rates increased dramatically. A significant 
complication of ART is multiple gestations. Approximately half of all children born 
subsequent to ART result from a plural gestation (Nakhuda and Sauer, 2005). Furthermore, 
the majority of triplets and higher order births are the product of ART. The risks for multiple 
pregnancies vary with practice patterns and the techniques used to achieve pregnancy. A 
healthy child delivered at term is the ideal endpoint of treatment for an infertile patient. 
Despite this general acknowledgment the current standards of care favour the risk of multiple 
pregnancies over the risk of failing to conceive (Nakhuda and Sauer, 2005). 
 
Multiple births are increasingly large contributors to the preterm and low birth weight 
population (Bryan, 2003) and always present a greater risk for mother and child (Scholz et 
al., 1999). The average duration of pregnancy is 37 weeks for twins, 33.5 for triplets and 31.5 
for quads. About 40% of twins and nearly all triplets and quads are born preterm (<37 
weeks). 50% of twins, 90% of triplets and nearly all quads have a birth weight of less than 
2500g. Half of the quadruplets weigh less than 1500g compared to a quarter of triplets, 1 in 
10 twins and 1 in a 100 singletons (Macfarlane et al. 1990). Several studies have found that 
IVF twin infants have a still greater tendency to prematurity and low birth weight than those 
that are naturally conceived (Lambalk et al., 2001). 
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Levene showed in 1991 that due to prematurity and low birth rates, mortality and morbidity 
rates are much higher in triplets than in singletons. Scholz et al. (1999) reported that postnatal 
problems result from multiple birth (29%) and prematurity (23%) and include: respiratory 
distress syndrome (RDS), persistent ductus arteriosus (PDA), bronchopulmonary dysplasia 
(BPD), septicaemia, intraventricular haemorrhage (IVH) and convulsions (Wilcox et al., 
1996). Infants also later show developmental delay, cerebral palsy and visual and hearing 
impairment (Gonen et al., 1990). 
 
There is also the social, psychological and financial burden of multiple births. Unexpected 
multiple births directly affect the available space and finances of the family and there are 
obligations to meet the needs of all the children, which results in lack of sleep and higher 
stress levels (Scholz et al., 1999). The risk of depression has been shown to increase with the 
number of multiple births (Thorpe et al., 1991) and the prognosis for both parents and 
children is often disappointing (Scholz et al., 1999). 
 
Given the personal and societal costs associated with the complications of multiple births, 
practice patterns of reproductive endocrinologists have public health implications (Nakhuda 
and Sauer, 2005). Techniques to reduce or eliminate the incidence of multiple gestations 
needed to be considered. Although techniques such as embryo freezing have been suggested, 
efforts to implement them into practice met resistance (Nakhuda and Sauer, 2005). 
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1.3. Embryo Selection Methods – A solution to multiple gestations in ART 
 
Identifying the embryos with optimized implantation competence for transfer, and those that 
have the highest probability of developing into a live baby, has been an issue of debate and 
continuous research. Embryo selection can take place throughout the development process. 
 
1.3.1. Embryo Development 
Insemination of the oocyte with the sperm cell is considered to be day 0. Fertilization is 
assessed on day 1, which is usually checked between 16-18 hours after the sperm cell is 
added to the oocyte. Normal and successful fertilization is evident if two pronuclei and two 
polar bodies can be seen. The pronuclei contain small nucleoli, which contain the genetic 
information from each respective parent. The pronuclei will eventually disappear with the 
union of two gametes, which is known as syngamy. The zygote is now on its way to 
becoming an embryo. Approximately 48 hours after the ova were first inseminated, the 
resulting embryos will usually have reached the 4 cell stage and after 72 hours the 8 cell 
stage. If the patient will be having pre-implantation diagnosis to test the genetic makeup of 
the embryo, the biopsy (removing a cell from the embryo to test) will usually be performed 
on this day.  
The embryo continues to divide, and there is increased cellular adhesion until the distinction 
between the blastomeres becomes difficult to see. The embryo at this stage is called a morula 
or a compact embryo and can be seen on day 4. 
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The morula will continue to develop and start to cavitate. The embryo begins to turn into a 
hollow ball of cells known as a blastocyst. A blastocyst is achieved 5 or 6 days after 
fertilization has taken place. The blastocyst consists of two main parts; an area denser with 
cells called the inner cell mass (ICM) which will eventually form the foetus, and the 
trophectoderm which lines the cell membrane and will go on to become the placenta.  
 
1.3.2. Embryo Selection Methods 
 
Implantation failure can be as a result of poor embryo quality and transfer techniques, 
endouterine abnormalities as well as immunologic dysfunction. Identifying the embryos with 
optimized implantation competence for transfer, and those that have the highest probability of 
developing into a live baby, has been an issue of debate and continuous research. Both 
invasive and non-invasive techniques have been established to facilitate a more effective 
selection process in order to improve transfer results.  
 
Non-invasive techniques include gamete/embryo grading and morphology, analysis of 
biochemical markers in culture media and culture to the blastocyst stage for selection. Earlier 
studies reported that morphological evaluations will furnish clues that enhance the ability to 
identify the best embryos for transfer (Shoukir et al., 1997) and pronuclear morphology has 
now been indicated as a method of selection for transfer (Scott et al., 2013). However, all 
these methods have significant limitations when it comes to predicting the likelihood of 
successful implantation and live births.  
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Research also shows that fast cleaving embryos resulted in a higher degree of developmental 
competence than slower ones (Windt et al., 2004; Kotze et al., 2013). Fast cleaving or early 
cleavage, is defined as the timing at which the first mitotic division, post fertilization takes 
place (Shoukir et al., 1997). This has been extensively studied to be used as additional criteria 
for embryo selection prior to transfer, as well as to predict embryo development potential and 
improved implantation/pregnancy rates (Kotze et al., 2013). Windt et al. (2004) performed a 
retrospective study to assess the effect that early dividing embryos (EDE) had on clinical 
pregnancy outcomes when compared to embryo transfers using late dividing embryos (LDE). 
It became evident that EDE used for embryo transfer showed increased ongoing and clinical 
pregnancy rates than those using LDE. This result was also replicated in the case of live 
births. Statistical evaluations also considered the number of embryos transferred and 
subsequently found EDE to be significantly favourable. Edwards and Beard (1999) also 
commented on the importance of the first cleavage and suggested that early selection criteria 
up to and including the first division may have advantages (Windt et al., 2004).   
 
Daily embryo scoring is used as another morphological evaluation. Many scoring methods 
have been published and cleavage stage morphological assessment is based mainly on 
blastomere number relative to time and the degree of fragmentation (Veeck, 2003). 
Blastomeres often divide evenly, although asynchronously, so it is not uncommon for 
embryos to have an odd number of cells and uneven blastomeres. The embryo is capable of 
repairing this itself. We can also see various indicators of poorer quality in the embryo at this 
stage; such as fragments or multinucleation of blastomeres. 
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Although many selection methods are promising, grading systems based on morphology 
remain the preferred way of assessing embryonic competence (Kirkegaard et al., 2012). The 
result of embryo scoring can change markedly within just a few hours (Montag et al., 2011) 
thus limiting the evaluation of a dynamic process by a few snap shots at discrete time points 
(Kirkegaard et al., 2012). The embryo scoring also relies on analysis outside of the incubator, 
which results in undesirable changes in temperature, humidity and gas composition (Zhang et 
al., 2010). More recently, Time-lapse monitoring (TLM) has been developed as a way of 
overcoming these obstacles. It involves cameras that are incorporated into the incubators and 
provides a promising clinical method of extending and refining morphological assessments 
that capture dynamic parameters (Kirkegaard et al., 2012). TLM subsequently has the ability 
to maintain samples in an optimal culture environment during the entire time of data 
acquisition (Wong et al., 2013). This novel, non-invasive technique ultimately increases the 
precision and sensitivity (Kirkegaard et al., 2012) of the favourable morphological evaluation 
technique. 
 
Invasive techniques, however, provide information about the chromosomal status of the 
embryo or specifically the ploidy (Kotze et al., 2012).  
Pre-implantation Genetic Diagnosis (PGD) was introduced in 1990 and involved using 
Fluorescent in Situ Hybridization (FISH) to identify aneuploidy and known single gene 
disorders in order to prevent their transmission. A few years later Kallioniemi et al. (1992) 
developed comparative genome hybridization (CGH) to screen the whole genome’s 
Deoxyribonucleic acid (DNA) in tumours. This technique was modified to study the DNA of 
single cells like blastomeres (Kotze et al., 2013). 
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Evidence shows that embryonic aneuploidy screening can improve clinical outcomes. Biopsy 
for PGD can be done at one or more of four possible developmental stages: (1) first polar 
body (PB) from oocyte (2) second PB from pronuclear embryo (3) blastomere biopsy 
obtained at cleavage stage or (4) trophectoderm biopsy at the blastocyst stage (Kotze et al., 
2013). It also needs to be considered whether screening is being done at the correct time and 
thus whether the abnormalities are being accurately identified, or whether it is too early to 
target the required genes. Subsequently there are queries as to whether the abnormalities 
identified correctly reflect a corresponding abnormality in the embryo or whether the embryo 
still has the ability to self-correct; whether the biopsy can be carried out with enough time to 
select for the most viable embryo and finally; whether the biopsy itself can compromise the 
embryo quality.  
 
The polar bodies are obtained early in the process and therefore allow more time for analysis. 
Evidence shows that 10% of PB abnormalities are as a result of nondysjunction and 90% are 
attributed to premature separation of sister chromatids (PSSC). These abnormalities will 
ultimately self-correct. PB screening indicates that 55% of embryos are anueploid. However, 
this means that 45% of this is due to PSSC and therefore provides suboptimal levels of 
diagnostic precision. PB biopsy also fails to identify approximately 40% of genetic errors 
(Scott et al., 2013).  
The safety of PB biopsy requires more evaluation. It is considered to be less invasive as it 
does not require removal of any portion of the actual embryo, even though it may play a role 
in its early organization. However, a recent study by Levin et al. (2012) showed that embryos 
that had been biopsied had more fragmentation and were less cellular but the critical end 
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point of implantation was not addressed and previous studies showed no adverse effect on 
implantation rates.  
Embryo biopsy is definitely more invasive than PB biopsy. At this stage, however, meiosis 
has been completed and both maternal and paternal errors can be detected, which overcomes 
some of the limitations of PB biopsy. In most circumstances a single blastomere biopsy is 
conducted and thus the detection of mosaicism is highly variable. It is assumed that the 
biopsy is an accurate representation of the entire embryo; however mosaicism has been 
shown to impact as much as 29% of all embryos. These embryos seldom implant, however it 
is one of the primary reasons why women who conceive with anueploid identified embryos 
should undergo antenatal aneuploidy screening (Levin et al., 2012). 
 
Biopsy is either conducted at the cleavage stage (day 3) of in vitro culture or at the blastocyst 
stage (day 5 or day 6). Day 3 biopsy still allows for a fresh transfer while only clinics with 
“in house” PGD laboratories will be able to continue with a fresh cycle following blastocyst 
biopsy. Both fresh cycle and vitrification cycles have shown to yield similar implantation and 
pregnancy rates. There is no clinically significant research to show that mosaicism is more or 
less prevalent during cleavage or blastocyst stage and is therefore a nonfactor in determining 
the optimal time for biopsy (Scott et al., 2013). The potential for self-correction at the 
embryo level should not influence the decision about the optimal time to biopsy.  
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Embryos biopsied at the cleavage stage sustained implantation rates of 30% in comparison to 
50% in non-biopsied embryos. This indicates sufficient harm rendering them incapable of 
implanting and progressing to term. A similar evaluation showed equivalent results for 
trophectoderm biopsy at blastocyst stage, however is it important to note that the only 
randomized controlled trials to ever demonstrate a beneficial effect both used trophectoderm 
biopsy. As of present, cleavage stage biopsy can be considered harmful while trophectoderm 
biopsy appears to be safe (Scott et al., 2013).  
 
Trophectoderm biopsies also contain multiple cells with an increased number of DNA copies 
for evaluation. This may help in reducing the nonresult screening rate and it is thus 
recommended that PGD biopsies be conducted through trophectoderm biopsy at the 
blastocyst stage.  
Previous invasive methods such as FISH showed that greater than 50% of embryos 
considered for transfer were in fact aneuploid. FISH however is limited by the amount of 
fluorochromes available and therefore only 12 of the 23 sets of chromosomes can be analysed 
at once. Problems such as mosaicism in day 3 blastomeres is also significant (Kotze et al., 
2013). 
Comparative Genomic Hybridization (CGH), however, allows for the entire karyotype to be 
analysed simultaneously. Polyploidy and balanced translocations cannot, however, be 
detected reliably and the hybridization process initially took up to 72 hours, which meant that 
embryos analysed for PB-I and PB-II ploidy could still undergo fresh transfers, whereas 
embryos biopsied on day 3 needed to be vitrified and transferred at a later stage (Kotze et al., 
2013).  
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Potentially detrimental effects of cryopreserving Pre-implantation Genetic Screening (PGS) 
embryos have been suggested by Zheng et al. (2005).  Researchers reported a 30%-40% 
reduction in their implantation potential. However, the recent the introduction of blastocyst 
vitrification (ultra-rapid freezing) has significantly improved the gamete/embryo 
cryopreservation process and consequently the survival of warmed embryos.  Sher et al. 
(2007) and Kotze et al. (2012) reported more than 50% live birth rates after the transfer of 
PGS vitrified/warmed blastocysts.  
The time taken to perform CGH required that biopsied blastocysts be cryopreserved and held 
until the results of CGH testing are available. Lately, a more rapid and detailed technology 
has been developed, namely CGH Array, allowing for the analysis of PB-I, PB-II, day 3 
blastomeres and trophectoderm cells (Hu et al., 2004; Wells et al., 2004; Le Caignec et al., 
2006; Treff et al., 2010) and also sebsequently avoiding the need for embryo 
cryopreservation.  
Metaphase CGH, or rather mCGH, uses this array technique, however it requires a far less 
amount of DNA, and can therefore effectively evaluate PBs. 
An article by Kotze et al. (2012) focuses on the significance of using oocyte/embryo ploidy 
status to achieve implantation and subsequent pregnancy rates. They therefore aimed to 
correlate first and second polar body ploidy, as well as day 3 blastomere ploidy and embryo 
morphology, with blastocyst development and in vitro pregnancy outcome. 57 oocytes from 
donors were analysed with the majority of which being aneuploid for PB-I, PB-II and day 3 
blastomere biopsies. 54.5% of the aneuploid embryos originated from the best graded group 
of embryos. Using mCGH they found a significant association between the CGH results of 
PB-I and PB-II respectively therefore indicating that each phase provides nearly the same 
information regarding their ploidy status.  This significant association was also evident 
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between the PB-I and blastomere biopsies as well as with the PB-II and blastomere biopsies, 
however, there was no association with subsequent blastocyst development with 62% of 
aneupoloid embryos reaching blastocyst stage. They therefore suggested that an embryo’s 
morphology cannot be correlated with its ploidy prior to transfer and the best way to select 
euploid embryos for transfer would be a combination of both morphologic and genetic 
testing.  
An interesting study conducted by Mertzanidou et al. (2013) showed that around 70% of 
good-quality embryos carry chromosomal abnormalities, including structural aberrations. In 
this study they analysed the majority of the blastomeres from top-quality embryos that 
originated from a cohort of embryos showing normal developmental rates and high 
implantation potential.  
 
With the development of extended embryo culture to the blastocyst stage there has also been 
much debate surrounding transfer at the cleavage or blastocyst stage. Both clinical pregnancy 
and live birth rates appear to be significantly higher in the latter group (Papanikolaou, 2008). 
 
We can conclude that a combination of both invasive and non-invasive techniques, such as 
those afore mentioned, as well as using biological markers as indicators will aid in selecting 
for the most optimal embryo for transfer.  
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1.4. Blastocyst Culture and Development of Sequential Culture Mediums 
 
Optimized blastocyst culture and transfer has also been shown to be a solution for multiple 
gestations. This is a result of being able to selectively choose, with greater integrity, the most 
viable embryo for transfer. 
 
Despite the fact that the first IVF pregnancy ever reported was from the transfer of a 
blastocyst (Edwards and Brody, 1995), the transfer of cleavage stage embryos dominated IVF 
for decades and resulted in implantation rates between 5% and 30% (Gardner et al., 1998). 
This was mainly due to difficulties in successfully culturing embryos to the blastocyst stage 
as the culture media used were not complex and did not completely support normal blastocyst 
development. In the early 1990s, knowledge of the metabolic requirements of the developing 
embryo increased and both co-culture techniques and sequential media were introduced 
(Hardarson et al., 2012; Gardner and Lane, 1998) and resulted in refined culture of embryos 
to the blastocyst stage. Implantation rates attained with the culture and transfer of human 
blastocysts are higher than those associated with the transfer of cleavage stage embryos to the 
uterus (Gardner et al., 2002; Papanikolaou, 2008). Such increases in implantation rates have 
facilitated the establishment of high pregnancy rates while reducing the number of embryos 
transferred (Gardner et al., 2002). 
 
Culture media aims to create an in vitro environment for the embryo which mimics that of the 
in vivo environment. The metabolic requirements of the embryo changes during development 
and Biggers et al. (2005) stated that the idea that sequential media is required for optimal 
embryo development therefore has an intuitive appeal. It is, however, not supported by direct 
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experimental evidence. It has, however, been suggested that a sequential media system is in 
fact used for embryo development to the blastocyst stage (Gardner and Lane, 1997). The 
composition of the culture media used for embryo culture from day 1 to day 3 of 
development will differ from that of the culture media used for subsequent culture to the 
blastocyst stage (Gardner and Lane, 1997; Gardner and Lane, 1998) in a sequential media 
culture system. 
 
Sepulvéda et al., (2009) however conducted a study to compare the in vitro development and 
pregnancy rates for embryos cultured in a single medium, with medium renewal on day 3, or 
in sequential media. All oocytes were obtained from young anonymous donors to minimize 
variability in the study. They found that embryos cultured in a single culture medium showed 
development that was morphologically just as good, if not better than those cultured in 
sequential media. After transfer of two morphologically comparable groups, implantation 
rates were recorded as being higher for those embryos cultured in the single culture medium 
as opposed to those in the sequential media system (Sepulvéda et al., 2009). The use of a 
sequential media culture system is therefore highly questionable (Sepulvéda et al., 2009). 
A study by Reed et al. (2009) also showed that for embryo transfer on day 5, there was a 
significantly higher mean number of blastocysts on day 5 in the single medium compared 
with sequential media (P<.05), and a significantly higher number of blastocysts were selected 
for transfer from the single medium compared with the sequential media, at approximately a 
2:1 ratio (P<.01).  Single culture mediums ensure less handling errors as well as reduced 
temperature and pH fluctuations (Lane and Gardner, 2005) and there is no apparent 
advantage in using sequential media systems (Sepulvéda et al., 2009).  
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This improvement in embryo culture dramatically increased the proportion of embryos 
developing to the blastocyst stage and therefore the application of blastocyst transfer in 
clinical IVF. The main objective of blastocyst culture was to increase the success rate of IVF 
because of better embryo selection after genomic activation and/or better endometrial 
synchronicity (Hardarson et al., 2012). Blastocyst culture has also been used to facilitate the 
morphological selection of the most viable embryo. This reduces the number of embryos 
transferred (Liebermann, 2009) and was proposed to reduce the incidence of multiple 
gestations. The ultimate goal of ART is to achieve a singleton, ongoing pregnancy. 
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1.5. Blastocyst Development and Grading 
 
As the popularity of blastocyst culture increased, so did the need for an effective 
morphological scoring system. One of the blastocyst grading systems introduced by Gardner 
and Schoolcraft in 1999 was quickly adopted by the majority of IVF laboratories (Veeck, 
2013). Although the system does not cover all aspects of blastocyst morphology, especially 
aberrant morphology, it has been very useful in classifying the degree of blastocyst expansion 
as well as the morphological appearance of the inner cell mass (ICM) and the trophectoderm 
(TE) cells (Hardarson et al., 2005). The blastocyst is therefore graded according to the degree 
of expansion, the ICM morphology and the TE morphology [Addenda 2 and 3]. 
A defining moment in embryonic development is when fluid starts to accumulate between 
cells at the morulae stage of development. As the fluid’s volume increases, a cavity appears 
and gradually forms the blastocoel. This normally happens between Days 4 and 5 in human 
embryos in vitro and marks the beginning of the blastocyst stage. As the fluid inside the 
newly formed blastocyst increases, so does the number of cells, and the combination of these 
two features causes a progressive enlargement of the blastocyst and it’s cavity with a 
consequent progressive thinning of the zona pellucida (ZP). Finally, the blastocyst breaks free 
of the ZP through a process called hatching (Hardarson et al., 2005). 
Blastocyst formation is initiated through an initial secretion between the morula cells and this 
small cavity is then maintained and increased by actions of the membrane channels.  Residing 
Na/K-ATPase channels raise the salt concentration within the embryo, attracting water 
through osmosis (Watson et al., 2004). This increased water pressure gradually increases the 
size of the cavity which continues throughout the blastocyst stages (Hardarson et al., 2005). 
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Embryos are graded according to the Gardner and Schoolcraft grading system (Veeck, 2003) 
[Figure 1] and the degree of expansion is noted accordingly [Addendum 2 and 3]. 
Once the blastocyst has reached an expansion grade of 3 or more, a clear distinction can be 
made between the two newly formed cell populations (Hardarson et al., 2005), namely the 
ICM and the TE. The destiny of the ICM is to become the embryo proper and its associated 
extra-embryonic structures. Morphologically, the ICM can range from being very large with 
tightly packed cells to almost non-existent with loosely bound cells (Hardarson et al., 2005; 
Veeck, 2003) [Addenda 2 and 3]. 
The number of cells composing the ICM can vary as well as the morphology of the cells 
within the ICM (Hardarson et al., 2005). Several studies have shown a positive correlation 
between the morphological appearance of the ICM to clinical outcome; the hypothesis being 
that the larger the ICM, the better the chances of a successful implantation (Balaban et al., 
2000; Richter et al., 2001). ICM cell numbers were found by Hardy et al. (1989) to double 
between days 5 and 6 (20.4 +/- 4.0 and 41.9 +/- 5.0, respectively) and remain virtually 
unchanged on day 7 (45.6 +/- 10.2). The shape of the ICM has been observed to be quite 
variable in appearance. It has been reported that the optimal shape of the ICM with respect to 
implantation potential is more oocyte-like in shape rather than the rounder or more elongated 
forms (Richter et al., 2001). 
Veeck (2003) [Figure 1] describes the ICM grading [graded as A, B C or D – Addendum 2 
and 3] as being either tightly packed or compacted cells, larger loose cells, where there is no 
discernible ICM and lastly whether the cells of the ICM appear degenerative.  
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The TE cells can be clearly distinguished from the ICM cells as the blastocyst begins to 
expand (Hardarson et al., 2005). The role of the TE cells in the early stages of blastocyst 
development is not entirely clear but their role in creating the fluid filled blastocoel may be a 
key parameter in ICM determination. The role of the TE cells, however, is better understood 
during and after implantation as they play a key role in apposition, adhesion and invasion of 
the endometrium, thus allowing the blastocyst to embed in the uterus. The TE cells also 
produce several molecular factors that aid in the implantation process (Aplin, 2000). Without 
properly functional TE cells, the embryo would remain within the ZP as these cells are 
actively involved in breaking free of the ZP (Sathananthan et al., 2003). The ultimate fate of 
the TE cells is to become the foetal extra-embryonic membranes as well as the placenta. 
Ahlstrom et al. (2011) have shown that for the first time the predictive strength of TE grade 
has a far greater predictive strength over ICM grading for selecting the best blastocyst for 
embryo transfer. It may be that, even though ICM is important, a strong TE layer is essential 
at this stage of embryo development, allowing successful hatching and implantation as 
opposed to a few cells that are compacted at one side or cells that appear degenerative. Hill et 
al. (2013) also stated that is has been increasingly shown that it’s the trophectoderm 
morphology grading rather than the inner cell mass morphology grading that significantly 
correlated with implantation and live birth after single-blastocyst transfer. This could reflect a 
positive embryonic condition in the interaction with the endometrium at the implantation site. 
Veeck (2003) [Figure 1] describes the trophectoderm [graded as A, B C or D – Addendum 2] 
as having either many healthy cells forming a cohesive epihelium; a few, but healthy cells, 
that are large in size; very large or unevenly distributed cells which may appear as a few cells 
that are compacted at one side or cells that appear degenerative.  
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1.6. Day 3 vs Day 5 Embryo Transfer 
 
Assisted reproduction programmes still lack high implantation rates but extending the 
duration of embryo culture to the blastocyst stage gives several theoretical advantages over 
the transfer of cleavage stage blastocysts. These include higher pregnancy rates, the 
opportunity to select the most viable embryo for transfer, the potential decrease in the number 
of embryos transferred, as well as better synchronization between the embryo and the 
endometrium at the time of synchronization (ASRM Practice committee 2014; Papanikolaou 
et al., 2008). It is generally assumed that blastocysts that develop in vitro in a timely manner 
are of better quality than those that develop more slowly (Veeck, 2003). Also, embryos with 
reduced viability will arrest in development and will not be cryopreserved (Alikani et al., 
2000). 
 
With the development of extended embryo culture to the blastocyst stage there has also been 
much debate surrounding transfer at the cleavage or blastocyst stage. The activation of the 
embryonic genome occurs three days post oocyte fertilization, after which the 8 cell stage has 
been achieved (Liebermann, 2010). Embryos transferred during and after this period are 
therefore known to have undergone genome activation (Desai et al. 2010; Papanikolaou et al., 
2008). Blastocysts develop following this 8 cell stage. Blastocysts increase the ability of a 
more accurate selection and therefore a lower number of embryos can be transferred, which 
will result in fewer high-order multiple pregnancies and increased implantation rates 
(Liebermann, 2009).Whether blastocyst-stage transfer offers any real benefit to infertile 
couples was debated in a Cochrane report by Blake et al. (2004).  In an updated Cochrane 
review published in 2012 both clinical pregnancy and live birth rates appear to be 
significantly higher in the blastocyst group (Blake et al., 2012) and made blastocyst culture a 
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popular embryo selection choice. We can speculate that this was as a result of increased 
numbers as well as refined culture systems. 
A prospective randomized controlled trial by Papanikolaou et al. (2008) demonstrated that, if 
a patient has at least four morphologically good embryos on the third day of embryo culture, 
extending culture to day 5 and transferring two blastocysts results in significantly higher 
ongoing pregnancy and live birth rates than when two embryos are transferred at the cleavage 
stage. However, this was at the cost of almost half of the patients in the blastocyst group 
initially having a multiple pregnancy (42.9 versus 29.6%, P > 0.05), which stresses the higher 
implantation potential of day 5 embryos in a selected patient population. 
 
This strategy, is reinforced by the widely acknowledged limitations of the morphological 
criteria used for the selection of cleavage-stage embryos (Rijnders and Jansen, 1988), and 
also by the large proportion of morphologically normal day-3 embryos that are 
chromosomally abnormal (Magli et al., 2000; Staessen et al., 2004). Papanikolaou (2008) 
stated that patients, however, whose embryos do not reach the blastocyst stage, are deprived 
of the chance of an embryo transfer and, potentially, a pregnancy (Jones et al., 1998a; 
Tsirigotis, 1998). It has, however, been shown that there is a positive correlation between the 
number of blastocysts developed and the number of eight-cell embryos formed on day 3 
(Jones et al., 1998b). This can therefore be used as an indication whether a blastocyst will 
develop. Furthermore, it has been suggested that patients with more than three 8-cell embryos 
on day 3 should be offered a blastocyst embryo transfer (Racowsky et al., 2000). 
Optimized embryo culture provided advances in embryo selection protocols. However, with 
this, came the problem of supernumerary embryos/blastocysts and freezing protocols were 
required to manage the numbers responsibly (Veeck, 2003). 
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1.7. The Effect of the Number of Embryos Transferred 
 
As mentioned previously, the goal of any fertility treatment is to achieve a single, ongoing 
pregnancy. Cryopreservation has allowed for single embryo transfer (SET) to occur by 
facilitating the freezing of supernumerary embryos for transfer at a later stage. This has also 
resulted in selective SET. Studies have been done to compare the outcome of single vs. 
multiple embryo transfer to determine the optimal number of embryos to transfer.  
The American Society for Reproductive Medicine reported in 2012 that in Europe, during 
2005, 20% of all ETs were SET. They summarized that there was no difference between the 
pregnancy rates and live birth rates of SET and double embryo transfers (DET). They also 
noted that SET was a more viable option for good prognosis patients (<35 years) than using 
selective methods for the most optimal embryo for transfer, and therefore confirming this 
exact guideline proposed by the ASRM in 2009. 
Jones et al. (1998b) reported that, in their study, the number of embryos transferred had a 
significant effect on clinical pregnancy. A greater chance of a clinical pregnancy was 
associated with an increase in the number of embryos transferred. Le Lannou et al. (2006) 
showed that the pregnancy rate was 27.6% in SET and 36.9% in DET in fresh cycles. SET 
was significantly lower (p<0.05) and was consistent with pregnancy rates of 14.4% and 
23.5% in frozen embryo transfers respectively. Gelbaya et al. (2010) confirmed this with a 
systematic review and meta-analysis where elective SET was reported to significantly reduce 
the probability of live births rates when compared to DET.  
This is confirmed in a recent summary of a Cochrane review (Pandian et al., 2014), which 
reiterates that SET is associated with fewer live births. 
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1.8. Blastocyst Cryopreservation 
 
1.8.1 Background 
 
The purpose of any cryopreservation technique is to ensure high survival rates of living cells 
after warming (Liebermann, 2003), and therefore to establish a protocol that does as little 
damage as possible to the embryo. Human blastocyst cryopreservation was first reported in 
1985 and was performed using glycerol in a series of ten increasing concentrations (Cohen et 
al., 1985). Blastocyst cryopreservation was initiated as a viable method of managing numbers 
of supernumerary embryos. 
Generally, cryopreserved embryos have a lower rate of pregnancy than fresh embryos 
(Hiraoka et al., 2008), which is thought to be as a result of ZP hardening during 
cryopreservation (Das et al., 2009). This would then create a negative effect on the natural 
hatching process of the embryo in vitro. More recent research, however, shows that the 
vitrified-warmed blastocyst transfer cycles resulted in statistically significantly higher clinical 
pregnancy rates as well as implantation rates, when compared to fresh cycles (Zhu et al. 
2011; Wu et al., 2014). 
 
Successful cryopreservation programs can also increase the treatment success of infertile 
patients since supernumerary embryos will be available for transfer at low additional cost. In 
fact, as a result of recent findings, frozen embryo cycle transfers are now suggested 
irrespective of supernumerary embryos, as they have been shown to lower multiple 
pregnancy rates while also improving clinical pregnancy outcome (Wu et al., 2014). 
Additionally, patients who are at risk of ovarian hyper stimulation syndrome (OHSS) can 
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vitrify all of the embryos in advance and reduce the likelihood of adverse clinical symptoms 
if a pregnancy is established (Veeck, 2003; AbdelHafez et al., 2010).  
The transfer of cryopreserved-warmed/warmed embryos account for more than 20% of ETs 
worldwide (Lieberman et al., 2003).  
 
1.8.2 Comparing Slow Rate Freezing and Vitrification 
 
The freezing procedure ultimately suspends all chemical and biological reactions, and under 
extremely cold liquid nitrogen storage (-196˚C) the embryos are able to undergo very long 
term storage. The total cryopreservation procedure involves the initial exposure to a 
cryoprotectant, cooling to sub-zero temperature, storage, warming, dilution and removal of 
the cryoprotectant, as well as the return of the biological material to a physiological 
environment (Liebermann, 2010). 
 
Initially slow rate freezing methods were used and were designed to create a delicate balance 
between damaging factors such as ice crystal formation, fracture, toxicity and osmotic 
damage (Vajta and Kuwayama, 2006). In the slow freezing method, done in a specifically 
designed machine, low concentrations of cryoprotectant are used and the cooling rate is 
relatively slow at 1.0°C/minute. The formation of ice crystals is a genuine threat and great 
care has to be taken to prevent them as they can be lethal (AbdelHafez et al., 2010).  
Slow freezing utilizes the equilibrium process to drive cellular dehydration, while slowly 
decreasing the temperature. Cooling rates lie between -0.5 - -5
o
C/min. This allows 
cryoprotectants to permeate the cell and ensure complete dehydration without 
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ice crystal formation. The embryos are cooled until their temperature has passed below -
30ºC, before being stored in liquid nitrogen at -196 ºC. Low concentrations of cryoprotectants 
in addition to varying sucrose or glycerol concentrations are used in the process (Youssry et 
al., 2008). Cryoprotectants can be toxic and non-toxic and also vary in permeability. 
Permeable cryoprotectants include Dimethyl Sulfoxide (DMSO), Propanediol (PROH), 
Glycerol and Ethylene Glycol. Sucrose is a non-permeable cryoprotectant. It is however 
soluble in water and creates dehydration in the cell by increasing the extracellular fluid as a 
result of diffusion. Sucrose also plays an important role in stabilizing the lipid bilayer and 
osmolarity. An increasing concentration of a cryoprotectant will result in an increasing 
toxicity level. A lower toxicity level cryoprotectant, however, does not vitrify the liquid as 
well. A perfect balance between reduction of intracellular ice formation and low toxicity 
needs to be created. Glycerol is incapable of completely vitrifying water and as a result is 
used in conjuction with other cryoprotectants. PROH has been found to be the most effective 
cryoprotectant (Lucci et al., 2002) with the highest the survival rate, blastocyst formation rate 
and blastocyst hatching rate of embryos (Wei-Xin et al., 2011) when compared to glycerol 
and DMSO. A successful combination is when PROH is used and the more toxic glycerol is 
added at a later stage during the process. 
Seeding is a crucial step that occurs during the freezing process. Supercooling is the ability of 
an aqueous solution, to cool down it’s normal freezing point, without changing it’s state; 
from liquid to solid (Özkavukcu and Erdemli, 2003). Seeding is where the solution is super 
cooled to below its freezing point, crystallization is introduced, and as a result the soloution 
immediately returns to its freezing point. Crystallization can be induced by particles within 
the medium, mechanical vibration or through rough surfaces (Özkavukcu and Erdemli, 2003). 
Seeding allows the temperature to remain relatively constant during the phase change from 
liquid to solid (ice). 
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Seeding prevents damaging effects from occurring to the embryo.  Seeding is initatited to 
propagate a series of latent heat peals down the vertical straw towards the bottom meniscus 
where the embryo is found. The ice moves along the wall and to the meniscus and then 
surrounds the embryo.  
 
Kuleshova and Lopata (2002) showed that the success of blastocyst cryopreservation with 
slow freezing protocols was not very successful, although a publication by the Alpha 
scientists group clearly shows that cryopreservation of human blastocysts are performed very 
successfully either by slow freezing or vitrification across the globe (Alpha Scientists in 
Reproductive Medicine, 2012).  Following their consensus meeting it was published that the 
fundamental principles of cryobiology suggest that the mechanisms leading to high survival 
of vitrified cells are similar, if not identical to the mechanisms resulting in survival of slow-
frozen cells. 
 
Edgar and Gook (2012) also concluded that although slow cooling of blastocysts has been 
reported to be inferior in some studies, others comparing the two approaches in the same 
clinical setting have demonstrated comparable results (Liebermann and Tucker, 2006). 
Ultimately successful blastocyst cryopreservation may be more consistently achieved with 
vitrification but slow cooling can produce similar results (Edgar and Gook, 2012). 
The development of a more rapid freezing method, otherwise known as vitrification, showed 
greatly improved outcomes in many studies (AbdelHafez et al., 2010; Mukaida and Oka, 
2012). AbdelHafez et al (2010) confirmed the findings by Loutradi et al. (2008) stating that 
vitrification resulted in significantly higher post warming survival rates when compared to 
slow freezing. They subsequently verified higher implantation rates as well as ongoing 
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pregnancy rates. Stehlik et al. (2005) demonstrated that vitrification of blastocysts showed 
significant improvement when compared to slow freezing of human blastocysts. Vitrification 
has higher efficacy and utilization rates (Liebermann, 2003), it maximizes the efficiency of 
IVF cycles (Liebermann, 2009), it is more time efficient and it is more cost effective as it 
does not involve expensive instrumentation (AbdelHafez et al., 2010). A thorough systematic 
meta-analysis conducted by AbdelHafez et al. (2010) shows that slow programmed freezing 
is still predominant; however there is a trend towards acceptance of vitrification in ART 
laboratories worldwide.     
Vitrification has been described as the achievement of a “state of suspended animation” 
wherein molecular translational motions are arrested without structural reorganization of the 
liquid. It involves placement of the embryo in a very small volume of vitrification medium 
that must be cooled at extremely high cooling rates (Liebermann, 2010). Vitrification has 
been endorsed by some to be the most promising method of preservation for tissues (Fahy et 
al., 2006). It was developed not only as a pure optimization of the slow freezing protocol; 
being quicker, less expensive, and reducing the limitations of the protocol to several cell 
types, but essentially to eliminate the incidence of cryoinjury. The most common of 
cryoinjuries are intracellular icicle formation and exposure to high salt concentrations, which 
needed to be eliminated. Cryoinjury may also occur as a result of osmotic swelling, osmotic 
shrinkage, fracture damage, chemical toxicity of the cryoprotectant, as well as extracellular 
ice formation (Liebermann, 2003). A typical embryo vitrification process cools the cells in 
the embryo at rates close to 20,000°C/minute (Loparatova et al., 2006) to a temperature of -. 
The vitrification medium will contain an intracellular cryoprotective agent (typically 
Ethylene glycol, DMSO and Sucrose), which will readily withdraw water from inside the cell 
as a result of a higher extracellular concentration of the cryoprotectant (Mazur, 1984). 
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Cryoprotectants also have the ability to lower the freezing point of a solution (Veeck, 2003). 
Vitrification cryoprotectants are highly soluble in water and form stable hydrogen bonds with 
the water molecules. This prevents a marked increase in salt concentration that would occur 
when freezing, by increasing the unfrozen fraction of water molecules and therefore 
preventing osmotic stress. Vitrification requires much higher concentrations of 
cryoprotectants than that used for slow freezing. Typically, embryos that are vitrified are 
exposed to 5-10 times more cryoprotectant than slow frozen embryos. The actual 
concentration depends on how fast the embryo can be cooled, and the faster the rate of 
cooling, the less cryoprotectant that has to be used. Of course biologists everywhere are 
sensitive to keeping cryoprotectant exposure to an absolute minimum; so much effort has 
gone into developing faster and faster cooling methods. 
The process of vitrification has 3 critical components. First, embryos/blastocysts are exposed 
to high concentrations of cryoprotectants to allow rapid dehydration of cells. Second, the 
embryos/blastocysts are loaded into tiny storage devices (specifically straws at Drs Aevitas 
Institute for Reproductive Medicine) that will facilitate ultra-rapid cooling, and third, the 
straws containing the embryos/blastocysts are cooled as fast as possible, typically at 
thousands of degrees per minute. 
Ultimate survival of cryopreserved cells and tissues may be more dependent on the rate at 
which the specimen is warmed rather than cooled (Leibo and Pool, 2011). A recent study 
showed that very rapid warming of slow frozen oocytes resulted in better outcomes 
(Parmegiani et al., 2014) with survival rates increasing significantly from 75% to 90.6%. The 
oocyte still remains the most fragile human cell with the highest risk of ice crystal formation 
and therefore cryoinjury during freezing/warming, due to an unfavourable nucleus/cytoplasm 
ratio and elevated intracellular water concentration (Parmegiani et al., 2014). Since the rapid 
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warming procedure proposed in their study is viable for oocytes, they suggest its potential for 
being applicable to other less fragile reproductive cells such as embryos. A recent study by 
Kojima et al. (2012) reiterated just that in a prospective study on slow frozen pronuclear 
embryos. They confirmed a positive effect on embryo development using the rapid warming 
protocol.  
Vajta and Kuwayama (2006) stated that vitrification can only be induced in exceptional 
situations, specifically with dangerously-high concentrations of cryoprotectants and/or with 
extreme increase of the cooling and warming rates (Vajta and Kuwayama, 2006).  
1.8.3. Factors Affecting the Success of Vitrification 
 
The success of a vitrification protocol depends on: (i) an optimal process of dehydration 
when cells are exposed to hypertonic conditions; and (ii) an ideal penetration rate of a non-
toxic cryoprotectant that is sufficient to generate an intracellular environment that will vitrify 
and remain vitrified for a defined cooling–warming rate (Alpha Scientists in Reproductive 
Medicine, 2012). The addition as well as the removal of the cryoprotectant causes successive 
phases of shrinkage and re-expansion due to movement of water as well as movement of the 
cryoprotectant across the cell membranes that are linked with several biophysical parameters 
(Alpha Scientists in Reproductive Medicine, 2012).  
1.8.3.1. Cooling rate and storage device 
Vitrification can be achieved either by direct (open system) or indirect (closed system) 
contact with liquid nitrogen (Papatheodorou et al.  2013) and by making use of varying 
loading devices and methods. As mentioned previously, a high cooling rate at vitrification, as 
well as a high warming rate at warming is required to facilitate the process successfully. 
Several devices have been designed to facilitate these high cooling rates and ideally there 
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should be no barrier between the oocyte/embryo and the liquid nitrogen (Vanderzwalmen et 
al., 2007; Alpha Scientists in Reproductive Medicine, 2012).This effort has yielded many 
storage devices that are only marginally bigger than the embryos being vitrified, to allow the 
fastest possible rate of cooling while keeping the embryos safely contained. The straws that 
are used to hold embryos during vitrification and storage are very small compared to the large 
½ and ¼ cc straws that are used with slow freezing. The amount of fluid surrounding a 
vitrified embryo is 100-200 fold less than what would surround a slow frozen embryo. 
Loading devices available today, to name but a few, include the Cryoloop, Cryotop® , 
Cryotip, Cryolock, Cut Standard Straws, Cryoleaf
TM
, Vitrisafe©, as well as High Security 
Straws 
TM
 (Kader et al. 2009).  Recently it has been reported that the open system is more 
successful than the closed system with respect to survival, fertilization, cleavage and clinical 
pregnancy rates, probably due to higher cooling rates (Paffoni et al. 2011). There are however 
safety concerns regarding the direct exposure of the embryos to liquid nitrogen 
(Papatheodorou et al. 2013) specifically due to the possibility of contamination and disease 
transmission (Vajta and Kuwayama, 2006). It has been proposed that contamination can be 
avoided by sterilized filtration of the liquid nitrogen (Lin et al. 2001), ultraviolet radiation 
(Parmegiani et al. 2010) and the storage of samples in vapors of nitrogen (Cobo et al. 2008; 
Eum et al. 2009). As a result, numerous amounts of research compare the open and closed 
systems. As mentioned previously research conducted by Paffoni et al. (2011) favoured the 
open system of vitrification. Nonetheless, Papatheodorou et al. (2013) showed that there is no 
significant difference between the two protocols and due to the safety concerns surrounding 
direct liquid nitrogen contact, suggest that the ultra-rapid vitrification may be replaced by 
aseptic vitrification without affecting clinical efficiency. The Vitrisafe© method is a closed 
system or direct method and makes use of a device consisting of two parts: a carrier called 
the Vitrisafe© and a 0.3ml high security straw (Papatheodorou et al.  2013). It consists of a 
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large gutter in which a small quantity of cryoprotectant (<1μl) containing the blastocysts can 
be deposited. Before placing the biological material into liquid nitrogen, the Vitrisafe© is 
inserted into the high-security 0.3 ml straw. For warming, the top of the outer straw is cut and 
the Vitrisafe© device is removed without contact with the liquid nitrogen 
The successful vitrification protocols for blastocyst cryopreservation have contributed to ever 
increasing rates of successful vitrification outcomes. Masashige Kuwayama was a pioneer in 
oocyte vitrification (Kuwayama, 2005) and also showed that the Cryotop® method of 
vitrification was the most successful (Kuwayama, 2007). This method is where vitrification 
occurs in <0.1µl medium droplet on the surface of a specially constructed fine polypropylene 
strip attached to a plastic handle. This was also reported by Vanderzwalmen et al. (2007) and 
along with other confirmations (Vajta and Kuwayama, 2006), it has resulted in its subsequent 
implementation today for blastocyst vitrification. 
 
1.8.3.2. Warming rate 
 
As mentioned previously, rapid cooling and warming rates are required for the induction of 
vitrification (Vajta and Kuwayama, 2006). Warming is conducted at 37°C. Vajta and 
Kuwayama (2006) also reported that as the cooling rate increases the cryoprotectant 
concentration can be lowered. Another characteristic of vitrification is that for any given 
concentration of cryoprotectant, the warming rates are much faster than the critical cooling 
rates (Fahy et al., 1987).   These high warming and cooling rates are what eliminate, either 
completely or partially, any chilling injury (Vajta and Kuwayama, 2006). This is possible due 
to the sample passing through the dangerous temperature zone too quickly for any damage to 
develop. 
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1.8.3.4. Blastocyst quality 
 
The selection criteria for the optimal embryos for cryopreservation and ultimately transfer, 
must include not only the daily grading procedures but also the original quality of the early-
stage embryo as well as the time taken to reach each stage of development (Liebermann, 
2009).  
Freezing protocols, as mentioned above, were designed to ensure optimal survival rates and 
to prevent any of the previously mentioned forms of cryoinjury, however, it is imperative that 
the blastocysts are of good quality before undergoing cryopreservation (Sunkara et al., 2010). 
Frozen–warmed blastocysts undergo multiple morphological changes including the collapse 
of the blastocoele cavity along with cellular lysis and degeneration (Alpha Scientists in 
Reproductive Medicine, 2012), which also needs to be considered. 
The blastocyst quality is determined morphologically by grading methods described, for 
example, by Gardner and Schoolcraft (Veeck, 2003) [Addenda 2 and 3]. It is commonly 
accepted that blastocysts which exhibit a clear, well-defined ICM and have an adequate total 
cell count are of better quality and deemed more viable for cryopreservation (Alpha Scientists 
in Reproductive Medicine, 2012). 
Some studies consider the time in which the embryo takes to reach blastocyst stage as the 
most important indicator of viability, while others argue that embryo viability is determined 
more accurately by the stage of development (Liebermann and Tucker, 2006).  
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1.8.3.5. Technical skill 
 
As with all laboratory procedures the skill of the technician plays a vital role. The experience 
as well as talent of the technician will contribute towards the success. Vitrification requires 
excellent skill, especially, to load the blastocysts onto the storage device with as little 
surrounding cryoprotectant as possible (FertiPro VitriFreeze
TM
-VitriWarming
TM
). This is 
essential to the vitrification success. 
 
1.8.3.6. Blastocoel collapsing 
 
A factor limiting the survival rate of the blastocyst during vitrification is the blastocoel. As 
can be expected, the formation of intracellular ice crystals is directly proportional to the 
volume of the blastocoel (Youssry et al., 2008).  It was shown that mechanically collapsing 
the blastocyst, described previously (Vanderzwalmen et al., 2002), facilitates the successful 
outcome of blastocyst vitrification (Vanderzwalmen et al., 2002; Son et al., 2003; Hiraoka et 
al., 2004; Mukaida et al., 2006). Vanderzwalmen et al. (2002) analysed the effectiveness of 
reducing the blastocoel volume, or rather, inducing the collapse of the blastocoel. The fluid in 
the cavity dilutes the cryoprotectant making it harder to expose cells inside the cavity to the 
full cryoprotectant concentration. Artificial shrinkage (AS) or collapsing is used to evade this 
concern. A small hole is made with a needle between two outer cells in the embryo to allow 
the fluid to escape from the cavity. As the fluid escapes, the embryo collapses in on itself 
giving the procedure its name. An increase in the survival rate of up to 70.6% was noted 
(Vanderzwalmen et al. 2002) and pregnancy rates also improved after the AS procedure. 
Other methods of AS also proved to be beneficial. In September 2004 a laser pulse generated 
by a laser system ZILOS-tk
TM
 (Hamilton Thorne Bioscience Inc., Beverly, MA, USA) was 
introduced to perform AS as an alternative to micro-needle puncture and is described by 
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Mukaida et al. (2006): The ICM should be located away from the targeted point of the laser 
pulse. One single laser pulse (200 ms) targeted at the cellular junction of the TE creates a 
hole to induce collapsing of the blastocoelic cavity. ICM and TE gradings are described in 
Addenda 3 and 4. Ideally you require a tight, compact ICM to significantly reduce the chance 
of damage caused by the laser or needle. The blastocoele of the expanded blastocyst shrinks 
immediately. This laser system does not require location and holding of the expanded 
blastocyst with a holding pipette or being connected to a micromanipulator. There were no 
statistically significant findings to differentiate between the micro-needle or laser pulse 
techniques (Mukaida et al., 2006), and although this technique (AS by means of laser) is 
notably simpler and convenient it is definitely a more expensive procedure. 
 
1.8.3.7. Day 5 vs day 6 Vitrification 
 
There was an increasing production of mid to fully expanded blastocysts on the 5
th
, 6
th
 and 7
th
 
day of embryo culture (Alpha Scientists in Reproductive Medicine, 2012), in which the 
expanded blastocoel cavity was evident.  
Some studies show that embryos frozen on day 5 have better implantation and clinical 
pregnancy rates in comparison to those frozen on day 6.  Liebermann and Tucker (2006) 
conducted a retrospective study which expressed vitrified-warmed day 5 embryos having 
survival, implantation and pregnancy rates as 95.9%, 33.4% and 48.7%. In comparison, those 
embryos frozen on day 6 resulted in rates of 97.5%, 25.9% and 42.8% respectively.  
However, cryopreservation on day 6 is still encouraged as it does result in live births 
(Liebermann, 2010). Richter et al. (2006) showed the embryos frozen at the expanded 
blastocyst stage had the similar viability, implantation potential and pregnancy outcome, 
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whether they were frozen on day 5 (32%) or day 6 (28%). However, the implantation and 
pregnancy rates for expanded day 7 blastocysts were lower (15%). McVearry et al. (2004) 
showed that these rates were still much higher than day 7 embryos transferred in a fresh 
cycle.  
Sunkara et al. (2010) conducted a systematic review and meta-analysis of controlled studies 
to compare pregnancy outcomes following transfer of warmed blastocysts that were frozen 
either on Day 5 or Day 6 following fertilization in vitro. They showed that ongoing 
pregnancy and live birth rates were higher for those embryos frozen on day 5 and a 
significantly higher clinical pregnancy rate for embryos frozen on day 5 was also reported. 
They also showed that there was no significant difference between the post-warming survival 
rates or the miscarriage rates of the two groups. It is, however, important to note that embryos 
having the same morphological grading, frozen on day 5 or day 6, showed no difference in 
clinical or ongoing pregnancy rates as well as live birth rates (Sunkara et al., 2010).  It is 
clearly evident that studies still yield inconsistent results (Liebermann and Tucker, 2006; 
Richter et al., 2006; Shapiro et al., 2008). 
 
1.8.3.8. Survival rate 
 
Implantation and Clinical Pregnancy rates have also been shown to rely largely on survival 
rates. The probability of implantation drops with a decrease in survival rates. Shipley et al. 
(2006) showed that implantation is relatively high when the majority of, if not all, cells 
survive, but begins to drop as cell survival declines below 95%. When fewer than 80% of 
cells survive, implantation potential appears minimal. 
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1.8.3.9. Assisted hatching 
 
Over the past 35 years there have been many advances in optimizing the treatment course for 
fertility, and despite this being highly beneficial it is still imperfect (Kissin et al., 2014). 
Kissin et al. (2014) describes Assisted Hatching (AH) as the purposeful disruption of the 
zona pellucida (ZP) layer surrounding the embryo and has been proposed as a method of 
improving favourable outcomes.  A Cochrane review emphasized that research conducted on 
fresh embryos showed no increase in favourable outcomes (Das, 2009), however it has been 
shown to benefit those women of increased age (Das, 2009; Liebermann, 2010) and in those 
women with repeated cycle failures (Chao et al., 1997; Das, 2009; Martins et al. 2011). It 
was noted in the Cochrane Review that there was a wide variation amongst the trials reported 
on in the review (Kissin et al., 2014). Limited research has been conducted with regards to 
AH in frozen warmed embryos, however, the available literature shows the procedure as 
being both beneficial (Tucker et al., 1991; Vanderzwalmen et al., 2003; Kung et al., 2003; 
Gabrielsen et al., 2004; Balaban et al., 2006; Petersen, 2006; Hiraoka et al., 2008; Valojerdi 
et al., 2008; Ge et al., 2008; Wan et al., 2014), with increased implantation rates (IR), 
pregnancy rates (PR) and LBR (live birth rates), as well as being non-beneficial (Edirisinghe 
et al., 1999; Ng et al. 2005; Sifer et al., 2006; Petersen, 2006; Aran et al., 2012). 
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Chapter Two 
 
Assisted Hatching on Vitrified/Warmed Embryos: 
A Survey of the Literature 
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2.1. Introduction 
 
A blastocyst is comprised of an inner cell mass, a blastocoel fluid cavity, and a 
trophectoderm layer lining the inside of the outer ZP. The ZP is a glycoprotein layer; made 
from acidic glycoproteins namely zona pellucida proteins 1, 2 and 3 (ZP1, ZP2 and ZP3), and 
surrounds the embryo during the preimplantation period (Veeck, 2003). This outer layer plays 
a vital role in maintaining the three dimensional structure of the precompacted embryo 
(Cohen, 1991). The ZP is known to prevent polyspermy, to protect the embryo from 
mechanical and immunological damage, and to preserve the integrity of the embryo during 
cleavage. It also plays a role in sperm cell binding and penetration as well as the induction of 
the acrosome reaction (Bleil and Wassarman, 1983; Bielfield et al., 1994). Bleil and 
Wasserman (1983) showed that mouse sperm recognize and bind ZP3 and that the binding 
thereof leads to the induction of the acrosome reaction. Experiments conducted by Bielfield 
et al. (1994) confirms that human ZP-sperm binding induces activation of multiple second 
messenger pathways, involving kinases, during the acrosome reaction.  
 
After the embryo compacts and the formation of cell junctions occur, blastocyst development 
follows and the ZP needs to be breached for the natural hatching process to occur. Hatching 
is described as the blastocyst escape through the ZP. It is a prerequisite for normal 
implantation as it facilitates trophoblastic invasion of the uterine endometrium (ASRM, 
2008). As the blastocyst expands during development there is an accumulation of fluid in the 
blastocoel, which results in increased pressure on the trophectoderm and ZP. The 
trophectoderm is also proliferating rapidly to form a cohesive monolayer.  Thinning of the 
zona occurs due to these physical pressures (Stein et al. 1995), however, it has been proposed 
that lytic enzymes released by the developing blastocyst may also play a combined role in the 
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hatching process (Schiewe et al, 1995). Gradual thinning of the zona, as well as changes in 
diameter before expansion occurs, are evidence of enzymes being involved. In vivo studies 
state that it is possible that the uterine enzymes are partly responsible for the complete 
shedding of the ZP (Lin et al. 2001).  Hatching sites are variable in humans but usually 
develop relatively close to the inner cell mass, in proximity to the polar trophectoderm. Small 
membrane vesicles can protrude from the ZP during in vitro culture, however they are not 
necessarily indicative of the subsequent hatching site. Once rupture of the ZP occurs the 
opening consists of one quarter to one third of the ZP, thus facilitating rapid and easy escape. 
The blastocyst begins to protrude from the ZP, while following the path of least resistance, 
but other mechanisms are thought to be involved in completing the hatching process. Actin 
polymerization is believed to play a role as actin filaments are highly concentrated on the 
trophectoderm cells, especially at the hatching site. When blastocysts hatch in vitro, small 
trophectoderm projections are observed outside of the ZP, which have been suggested to 
serve as the first contact between the blastocyst and the uterus, since they are localized to the 
precise region that will ultimately attach to the uterine epithelium (Veeck, 2003). In vitro 
hatching of healthy human blastocysts typically occurs on day 6 or 7 of culture (Sathananthan 
et al., 2003) otherwise on day 5 if the zona has been manipulated (Das et al., 2009). 
Hardening of the ZP is speculated to occur spontaneously during in vitro culture as well as 
during cryopreservation (Vanderzwalmen et al., 2003) due to the cryoprotectant (Larman et 
al., 2006). Zona hardening is a result of the fusion of cortical granules to the plasma 
membrane and the release of their contents into the ZP layers (Matson et al., 1997). This 
hardening may impair successful embryonic hatching and implantation (Shi et al., 2013).  
Larman et al. (2006) conducted an experiment in mice to compare the effects of two 
commonly used cryoprotectants used in vitrification procedures, namely DMSO and ethylene 
glycol, on ZP hardening. Both cryoprotectants were found to cause a large transient increase 
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in intracellular calcium concentration in mouse metaphase II (MII) oocytes, which was 
comparable to the initial increase triggered at fertilization. When they removed the 
extracellular calcium from the medium surrounding the oocytes, the increase in intracellular 
calcium was unaffected in the presence of DMSO. It was, however, significantly reduced in 
the presence of ethylene glycol. This suggests that the source of the DMSO-induced calcium 
increase is solely from the internal calcium pool, as opposed to ethylene glycol that causes an 
influx of calcium across the plasma membrane from the external medium. They also carried 
out vitrification in calcium-free media which resulted in significantly reduced ZP hardening 
and subsequent fertilization and development to the two-cell stage was significantly 
increased. 
This supports the idea that ZP hardening is an early activation event that is triggered by the 
sperm-induced calcium increase observed at fertilization (Homa and Swann, 1994) and that 
the addition of cryoprotectants serves to exacerbate this process. 
Since it is widely accepted that the implantation potential of a frozen warmed embryo is 
lower than that of a fresh embryo (Debrock et al., 2011) and that this may be a result of ZP 
hardening, AH of the ZP was introduced into fertility treatment programmes to breach the 
hardened ZP and promote the natural process of hatching (Gabrielsen et al., 2004). AH was 
first introduced in the 90’s using Acid-Tyrode’s solution (Cohen, 1991).  
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2.2. Assisted Hatching of Blastocysts 
 
2.2.1. General 
 
AH involves creating an artificial hole or thinning in the ZP to facilitate the natural hatching 
process while in vitro. It was originally suggested due to an observation that microsurgically 
fertilized embryos with artificial gaps in their ZP appeared to have higher rates of 
implantation (Cohen et al., 1989). Cohen et al. (1990) and Kissin et al. (2014) accurately 
described the benefits and disadvantages of AH and how the adoption of new technologies 
should involve a thorough and proven risk/benefit ratio for validity and efficacy prior to 
implementation, but the rate of scientific progress often supersedes the ability to do so. 
Retrospective studies have therefore been of great scale on this topic. A thorough analysis of 
retrospective data was reviewed on AH in fresh cycles in the United States over the years 
2000-2010 (Kissin et al., 2014). Kissen et al. (2014) showed that cycles involving AH 
increased significantly from 25 724 to 35 518 over the 10 year period (p=0.002). Despite the 
increase in its implementation, they reported that AH was associated with decreased odds of 
implantation, clinical pregnancy, live births and an increase in miscarriage rates. In the case 
of poor prognosis patients there was no significant difference in pregnancy outcomes. As 
mentioned previously, in a Cochrane review no significant difference in live birth rates 
between assisted hatching groups and control groups in fresh ART cycles was found (Das, 
2009). This was supported in a systematic review and meta-analysis conducted by Martins et 
al. (2011). 
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2.2.2. Controversial Findings 
 
There is however evidence that shows that AH is beneficial after numerous failed fresh and 
frozen warming IVF cycles (Chao et al., 1997; Das, 2009; Martins et al., 2011) as well as in 
women of increased age (Das, 2009; Liebermann, 2010). The improved clinical pregnancy 
rates were 74% in frozen cycles and 25% in fresh cycles. Smaller numbers were used, 
however, and they insist that a randomized control trial is necessary to be able to conclude 
whether AH is beneficial in frozen warming embryo cycles. Martins et al. (2011), however, 
found no significant advantage associated with women of increased age.  
 
2.2.3. Types of AH 
 
Hatching of the zona has been performed mechanically (Cohen et al., 1990), chemically 
(Cohen et al., 1992), or by the use of laser (Palankar et al. 1991; Antinori et al., 1996). 
Otherwise denoted as mechanically assisted hatching (MAH), chemically assisted hatching 
(CAH) and laser assisted hatching (LAH). Acid tyrodes, proteinases, piezon vibrator 
manipulators and lasers are used (Hammadeh et al., 2010). An increased implantation rate after 
mechanical thinning of the ZP was first reported in 1990 (Cohen et al., 1990) and CAH using 
acidified Tyrode’s solution to drill through the ZP suggested improved implantation rates when 
selectively performed on poor prognosis patients (Cohen et al., 1992).  LAH is more widely 
used because it is easier to control and is more precise (Sagoskin et al., 2007), whereas the 
chemical and mechanical techniques require extensive technical skill (Hammedeh et al., 2010). 
Hammedeh et al. (2010) also emphasized the need to minimize the time that the embryo is kept 
outside the incubator and therefore to optimize the methodologies to reduce both pH and 
temperature variations that could be detrimental to embryo development. MAH involves the 
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use of a microneedle or, more recently, piezo technology. In the case of a microneedle, Partial 
Zona Dissection (PZD) is performed while the embryo is stabilized using a holding pipette and 
then pierced with the microneedle tangentially through the space between the ZP and the 
blastomeres until it pierces through the ZP again (Cohen et al., 1990). The small part of the ZP 
that is trapped against the microneedle is then rubbed against the holding pipette, and therefore 
creating an opening between the two sides that have been pierced (Hammedeh et al., 2010). 
Piezo technology was later introduced for ZP drilling (Nakayama et al., 1999). Nakayama et al. 
(1999) described how, while a holding pipette anchors the embryo, vibratory movements 
produced by a piezo-electric pulse regulated by a controller are used to carve a limited conical 
area in the ZP. Numerous applications in adjacent areas serve to produce a large hole, which 
facilitates complete hatching of the blastocyst (Hammedeh et al., 2010). CAH is done using 
acidified Tyrode’s solution and has previously been described in detail by Cohen et al. (1990; 
1992). They explain that, as with MAH, the embryo is secured using a holding pipette and the 
microneedle is applied to a blastomere-free area. The microneedle is preloaded with acid 
Tyrode’s solution using mouth-controlled suction. The solution is expelled gently and once the 
ZP has been breached suction is applied to prevent any excess solution entering the perivitteline 
space. The ZP dissolves instantly and the embryo is then immediately removed to be washed 
and therefore remove any trace of the acid (Hammedeh et al., 2010). Finally, LAH, was first 
reported in 1991 (Palankar et al., 1991). After advances in the technology, there is a general 
preference of a non-contact laser mode using a 1.48 µm diode laser, which was reported by 
Blake et al. (2001). Hammedeh et al. (2010) stated in their summary of the literature that LAH 
would appear to be associated with the lowest potential risk and that it is relatively simple to 
perform with consistency between operators. Initially a complete hole was made to breach the 
ZP until improved pregnancy outcomes were reported by Blake et al. (2001) where they used 
the laser to thin the ZP rather than producing a full thickness hole. This was then confirmed in a 
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subsequent study by Mantoudis et al. (2001). There is no ultra-structural damage associated 
with LAH, which was confirmed using both light electron microscopy and scanning electron 
microscopy (Obtruca et al., 1997).  AH has, however, been associated with an increased risk of 
monozygotic twinning (Hershlag et al. 1999; Schieve et al. 2000). Ultimately, results between 
these methodologies vary and are likely due, at least in part, to variations in the level of 
experience and hatching methods (ASRM, 2008).  
 
All these methods aim to create a hole in the ZP (Primi et al., 2004; Valojerdi et al., 2008) or 
can also be used purely as a thinning technique (Debrock et al., 2011) to facilitate the escape 
from a possibly altered ZP. This will assist the embryo in hatching out of the ZP once the 
blastocyst has expanded and is ready to implant. This also ensures an earlier contact time 
with the endometrium (Hammedeh et al, 2010). Liu et al. (1990) showed that early 
implantation is associated with subsequent viable pregnancies, while delayed implantation is 
associated with a high incidence of miscarriage.  
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2.3. Assisted hatching in vitrified warmed cleavage stage embryos and            
      blastocysts – results from the literature 
 
To overcome the occurrence of zona pellucida hardening (Larman et al., 2006) and to 
therefore circumvent the resulting impairment of successful hatching and implantation, AH 
was introduced as a possible solution and became implemented in IVF programmes 
worldwide. Research was conducted on embryos, first, during fresh cycles (Chao et al., 1997; 
Das, 2009; Leibermann 2010) and, as previously mentioned, it was only shown to be 
beneficial in repeated cycle failures as well as in women of increased age. 
 
The benefit of AH on frozen warmed embryos is more inconclusive. Some studies show it to 
be beneficial (Tucker et al.,1991; Vanderzwalmen et al., 2003; Kung et al., 2003; Gabrielsen 
et al., 2004; Balaban et al., 2006; Petersen, 2006; Hiraoka et al., 2008; Valojerdi et al., 2008; 
Ge et al., 2008; Wan et al., 2014), while others do not (Edirisinghe et al., 1999; Ng et al., 
2005; Sifer et al., 2006, Petersen, 2006; Aran et al., 2012). The Cochrane Review on Assisted 
Hatching in IVF and ICSI in 2006 showed that there is a benefit in women with repeated 
cycle failures as well as in those women with poor prognosis embryo transfer cycles, 
however, this is inconclusive (Das et al., 2009). 
We conducted a survey of the literature and report back on 16 studies that have been carried 
out on frozen warmed embryos. There is very limited research that has been conducted and as 
a result we have included data on cleavage stage embryos as well as blastocysts, which also 
allows a comparison thereof. The results have been summarized and are presented in Tables 
2.3.1, 2.3.2 and 2.3.3.  
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Table 2.3.1: Summary of descriptive information from publications found in a literature search regarding 
assisted hatching [AH] on vitrified/warmed embryos 
 
Article 
Number of Cycles Age at Freezing Embryo 
Stage 
CTRL AH CTRL AH 
Tucker et al., 1991 63 64 no data no data blastocyst 
Edirisinghe et al., 1999 no data no data no data >38 blastocyst 
Vanderzwalmen et al., 2003 49 36 27-41 27-41 blastocyst 
Kung et al., 2003 NA 89 NA 31.70 cleavage 
Gabrielsen et al., 2004 117 136 32.8 33.10 cleavage 
Ng et al., 2005 80 80 34.00 34.00 cleavage 
Sifer et al., 2006 61 64 32.00 32.30 cleavage 
Balaban et al., 2006 183 183 32.7 32.40 cleavage 
Petersen, 2006 110 110 32.5 31.70 cleavage 
Petersen, 2006 19 19 30.1 32.10 cleavage 
Hiraoka et al., 2008 30 40 31.00 32.00 blastocyst 
Hiraoka et al., 2008 30 31 31.00 33.00 blastocyst 
Valojerdi et al., 2008 90 90 31.79 31.18 cleavage 
Ge et al., 2008 100 100 30.66 31.84 cleavage 
Wan et al., 2014 102 96 32.60 33.10 blastocyst 
Zhou et al., 2014 335 480 29.90 29.73 cleavage 
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Table 2.3.2: Summary of descriptive information from publications found in a literature search regarding 
assisted hatching [AH] on vitrified/warmed embryos (continued) 
 
Article 
Number of 
blastocysts 
transferred ICSI/IVF 
Type of 
AH 
AH before 
(B) or after 
(A) 
vitrification 
Complete 
Hole (CH) 
or Partial 
Thinning 
(PT) 
CTRL AH 
Tucker et al., 
1991 no data no data no data mechanical A PT 
Edirisinghe et 
al., 1999 no data no data ICSI mechanical A no data 
Vanderzwalmen 
et al., 2003 2.00 2.00 ICSI/IVF mechanical A PT 
Kung et al., 
2003 NA 2.50 ICSI/IVF laser B PT 
Gabrielsen et 
al., 2004 1.91 1.94 ICSI/IVF chemical A PT 
Ng et al., 2005 1.00 1.00 ICSI/IVF laser A CH 
Sifer et al., 
2006 2.00 2.00 ICSI/IVF chemical A PT 
Balaban et al., 
2006 3.10 2.90 ICSI laser A PT 
Petersen, 2006 2.75 2.69 ICSI laser A PT 
Petersen, 2006 2.60 2.9 ICSI laser A PT 
Hiraoka et al., 
2008 2.70 2.6 ICSI laser A PT (40µm) 
Hiraoka et al., 
2008 2.70 3.00 ICSI laser A PT (50%) 
Valojerdi et al., 
2008 3.14 3.29 ICSI/IVF laser A CH 
Ge et al., 2008 2.46 2.33 ICSI/IVF laser A PT 
Wan et al., 
2014 max 3 pp max 3 pp ICSI/IVF laser A CH 
Zhou et al., 
2014 
2.48 2.48 ICSI/ IFV laser A PT 
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Table 2.3.3: Summary of descriptive information from publications found in a literature search regarding 
assisted hatching [AH] on vitrified/warmed embryos (continued) 
 
Article 
IR (%) PR (%) LBR (%) 
Beneficial 
(Y/N) 
CNTRL AH CNTRL AH 
CNTR
L 
AH 
Tucker et al., 
1991 9.00 16.00 no data no data no data no data Y 
Edirisinghe et 
al., 1999 13.30 0.00 16.70 5.00 no data no data N 
Vanderzwalme
n et al., 2003 13.00 22.00 19.00 38.00 no data no data Y 
Kung et al., 
2003 NA 16.90 NA 31.40 no data no data Y 
Gabrielsen et 
al., 2004 5.80 11.40 11.10 17.60 no data no data Y 
Ng et al., 2005 6.80 9.00 15.00 12.50 no data no data N 
Sifer et al., 
2006 9.20 9.60 17.20 18.00 no data no data N 
Balaban et al., 
2006 9.90 20.10 27.30 40.90 no data no data Y 
Petersen, 2006 8.60 8.10 18.20 18.20 no data no data N 
Petersen, 2006 14.30 27.80 31.60 47.40 no data no data Y 
Hiraoka et al., 
2008 10.00 27.00 17.00 43.00 no data no data Y 
Hiraoka et al., 
2008 10.00 52.00 17.00 74.00 no data no data Y 
Valojerdi et al., 
2008 4.20 12.80 11.10 31.20 no data no data Y 
Ge et al., 2008 7.30 16.70 14.00 25.00 no data no data Y 
Wan et al., 
2014 23.60 34.20 35.30 51.00 28.40 40.60 Y 
Zhou et al., 
2014 
16.95 31.85 33.43 53.96 23.88 43.58 Y 
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Table 2.3.1, 2.3.2 and 2.3.3 show that the available data from the literature included 16 
control and 16 matched AH cycles. One study had no control group and compared their AH 
results to previous data and literature. Statistics were calculated using the Independent t-Test. 
The average female age for the control group was 31.92 and 32.37 for the AH group. There 
was no significant difference between the ages of the women in the different studies or the 
number of embryos transferred in each cycle (P=0.9). The average number of embryos 
transferred in each cycle in the control group was 2.39 and 2.42 for the group undergoing 
AH. Again, there was no significant difference between the two groups. 
 
 62.5% [10/16] of the studies performed AH on cleavage stage embryos. 75% [12/16] of the 
studies showed that AH is beneficial in frozen warmed embryos (including the study where 
AH was performed prior to vitrification). This is statistically significant with a P value of 
0.0356. Only one of the included studies did AH before cryopreservation and did not include 
a control group. Of the studies showing no benefit for AH in frozen warmed embryos, 75% 
were associated with AH being performed in the cleavage stage, however this is non-
significant (P= 0.35). Within this group there was no association to the type of AH performed 
as well as to whether a complete hole was created during AH or if only a portion of the ZP 
was thinned during AH. Where LAH was performed, there was an 81.81% [9/11] benefit, 
MAH had a 66.67% [2/3] benefit and CAH had a 50% [1/2] benefit for frozen warmed 
embryos, and subsequently no significant association was reported.  
 
In the case of Partial Thinning, 83.33% [10/12] of studies had beneficial results, and where a 
complete hole was created, a 66.67% [2/3] benefit was observed. The most viable 
methodology, however, could not be statistically identified (P=0.53).  
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Edirisinghe et al. (1999) as well as Ng et al. (2005), Sifer et al. (2006), Petersen (2006) and 
Aran et al. (2012) showed that AH was not beneficial for frozen warmed embryos, however it 
was also found in several other studies that AH on frozen warmed embryos improved 
implantation rates and pregnancy rates respectively (Tucker et al., 1991; Vanderzwalmen et al., 
2003; Kung et al., 2003; Gabrielsen et al., 2004; Balaban et al., 2006; Petersen, 2006; Hiraoka 
et al., 2008; Valojerdi et al., 2008; Ge et al., 2008; Wan et al., 2014). 
 
From the tables shown we calculated the average implantation rate for the control group to be 
10.35% compared to an increase to 18.9% for the AH group. This increase was also apparent 
for pregnancy rates: 19.2% vs 32.3%. The Independent T Test calculated the P values to be 
0.53 and 0.47 respectively and the differences are therefore non-significant. In two studies 
where live birth was recorded AH of frozen warmed embryos also showed increased rates 
28.4% vs 40.6% for control and AH cycles respectively. This would indicate a benefit, however 
the numbers too small to be conclusive.  
From this data we can identify trends; however, the numbers of studies, to date, are too small 
to viably and significantly be compared. As a result, it is still controversial as to whether 
assisted hatching does indeed play a vital role in the implantation and survival of the frozen-
warmed embryo, and consequently there is a need for numerous more studies on a larger 
scale. A meta-analysis should also be conducted on the collected data. Most of the research to 
date has been conducted on cleavage stage embryos and is therefore more conclusive (Kung 
et al., 2003; Gabrielsen et al., 2004; Ng et al., 2005; Sifer et al., 2006; Balaban et al., 2006; 
Petersen, 2006; Petersen, 2006; Valojerdi et al., 2008; Ge et al., 2008; Zhou et al., 2014). To 
clarify whether AH on frozen warmed blastocysts, however, is indeed beneficial we plan to 
design a prospective study in which this can be evaluated. 
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Chapter Three 
 
Aim and Objectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
52 
 
The aim of this study is to optimize the outcomes of human blastocyst vitrification in an ART 
programme. To do so, we have designed a Retrospective Study to report back on the 
established Vitrification/Warming Programme in place at Drs Aevitas Institute for 
Reproductive Medicine over a period of 10 years. A thorough analysis of the data, and 
comparison with available literature, will allow us to identify strengths as well as weaknesses 
within the programme and suggest ways of improving and therefore optimizing the outcomes. 
Consequently we have also designed a Prospective Study to confirm our speculations and 
ultimately further refine the programme.   
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Chapter Four 
Materials and Methods 
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4.1. Retrospective Study 
 
Title: 
Human blastocyst Vitrification:  A retrospective review of outcomes at an Assisted 
Reproductive Technology (ART) clinic [2004-2014] 
The study was conducted using the database of patient files at Drs Aevitas Institute for 
Reproductive Medicine at Life Vincent Pallotti Hospital. Patients are included over a period 
of ten years from 2004-2014. Ethical Approval from the Health Research Ethics Committee 
of the University of Stellenbosch (HREC) was obtained [S13/05/102] on 18 September 2013 
and all data obtained from the patient files remained anonymous in the study. No funding was 
required for data collection. 
The Materials and Methods described in this Chapter pertain to standard protocols and 
procedures that patients frequenting the clinic undergo during Assisted Reproductive cycles. 
Detailed methodologies are presented as Addenda in Chapter Nine. 
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4.1.1. Methods  
 
4.1.1.1. Patients 
 
Standard IVF and intracytoplasmic sperm injection (ICSI), physiological intracytoplasmic 
sperm injection (PICSI) and intracytoplasmic morphologically selected sperm injection 
(IMSI) patients with stored, vitrified blastocysts were included. All female ages and all 
semen profiles were included. 
4.1.1.2. Ovarian Stimulation and oocyte aspiration  
 
Different but standard, routine procedures were followed for ovarian stimulation. A routine 
oocyte aspiration protocol (using a sonar guided method) was followed [Addendum 7]. 
4.1.1.3. Semen preparation and insemination 
 
Standard procedures for semen production and preparation were followed. Both the swim up 
and gradient centrifugation preparation methods were done depending on the semen 
characteristics [Addenda 5 and 6]. 
Standard IVF and ICSI insemination procedures were followed [Addenda 8 and 9].  
4.1.1.4. Embryo culture and evaluation 
 
All embryos were cultured and graded using standard protocols used at Drs Aevitas Institute 
for Reproductive Medicine [Addendum 2]. Blastocysts were graded according to the Gardner 
and Schoolcraft [Addenda 3 and 4] grading method (Veeck, 2003).  
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4.1.1.5. Morula and Blastocyst Vitrification 
 
Supernumerary embryos/blastocysts of good quality after fresh embryo transfer were vitrified 
on day 5 or day 6 (and in some instances on day 7), following a modified protocol designed 
for Cryotop® (Kitzimato®) vitrification (Cobo et al., 2008) with accordance to the Ferti-
Pro® Vitri Freeze kit protocol [Addendum 10], and currently being used at Drs Aevitas 
Institute for Reproductive Medicine. 
 
4.1.1.6. Blastocyst Vitrification [Addendum 12] 
 
 Vitrification was performed at room temperature and it was therefore ensured that the 
heated stage was turned off. 
 Two pulled glass pipettes were made and used for embryo manipulation. 
 A coloured Cryotop® was chosen and labelled with the patient’s initials and surname, 
ID number and date of vitrification on alternating sides at the top of the Cryotop® 
using an IVF-safe permanent marker.  
 Blastocysts with an expansion grading of a 2 or higher were collapsed using a 
collapsing dish and micromanipulation needles. Collapsing was done at 37°C in drops 
of flushing medium covered with oil on a heated stage [Addendum 13]. 
Note: it is not necessary to collapse a hatched or hatching blastocyst. 
 Vitrification media (Fertipro® “VitriFreeze”) was aliquotted into labelled Eppendorf 
tubes. 
1: VitriFreeze Pre-incubation medium (200µl per patient) 
2: VitriFreeze Freezing medium1 (100µl per patient) 
3: VitriFreeze Freezing medium2 (100µl per patient) 
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4.1.1.7. Blastocyst Warming [Addendum 14] 
 
The blastocysts were warmed, again according to the routine, standard protocol in accordance 
with the Ferti-Pro Vitri Warming kit protocol (Addendum 4) used at Drs Aevitas Institute for 
Reproductive Medicine.  
 Warming was performed on a heated stage measuring 37°C. 
 Warming medium was warmed a minimum of 1 hour before (or the day before) to 
ensure a temperature of 37°C. 
- VitriWarming 1 (1000µl per patient) 
- VitriWarming2 (200µl per patient) 
- VitriWarming3 (200µl per patient) 
- VitriWarming4 (200µl per patient) 
 A centre well dish was also incubated to 37°C in the same fashion. 
 Enough pulled pipettes were available for blastocyst manipulation. 
 
4.1.1.8. Blastocyst Vitrification and Warming (Vitriplug Method) 
 
In earlier years, more specifically from 2004 up until 2008, the Vitriplug method of 
cryopreservation and warming was used in our laboratories. As a result, data collected from 
the initial cycles will have followed this alternate procedure. A detailed description can be 
found in Chapter 9 [Addendum 15]. 
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4.1.1.9. Embryo Transfer [Addendum 16] 
 
A minimum incubation time of three hours post warming was utilized prior to blastocyst 
transfer. This allowed adequate time to ensure survival of the frozen/warmed blastocyst. 
A standardized blastocyst transfer method (using sonar guidance) was performed. Blastocysts 
were transferred with the patient having been instructed to present with a full bladder. 
 
4.1.1.10. Human Chorionic Gonadotropin (HCG) Levels 
 
A quantitative βHCG was performed to determine early pregnancy, which can be 
extrapolated to an implantation rate. Blood was drawn according to standard procedure 
[Addendum 17] using a Vacutainer © on days 10 and 14 following embryo transfer.  
 
4.1.1.11. Recording of Patient Information 
 
Patient files included a daily embryo scoring sheet and embryo freezing and transfer is duly 
noted in the respective files. Forms for embryo freezing [Addendum 11] were also completed 
and stored separately in folders, along with duplicated patient information and consent forms 
respectively. A thorough analysis of prospective patient files and Embryo Vitrification 
folders was conducted. The Excel spread sheet created (including data of the fresh, 
cryopreservation and warming cycles) allowed for analysis of: 
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1) Descriptive Statistics 
 
Incidence of survival rates [2004-2014] after warming of vitrified blastocysts. 
Biochemical Pregnancy Rates [2004-2014]  
Clinical Pregnancy Rates [2013-2014]  
Incidence of female (oocyte) age in vitrification/warming cycles [2004-2014] 
Incidence of vitrification in warming cycles on different days of blastocyst 
development [2004-2014] 
Incidence of Donor Oocyte vitrification cycles [2004-2014] 
Number of embryos transferred/cycle [2004-2014] 
Incidence of Good Quality Embryos before Vitrification [2004-2014] 
Incidence of Good Quality Embryos post Warming [2004-2014] 
Incidence of Fresh Pregnancy Cycles in patients with frozen embryo transfers [2004-
2014] 
The incidence of FET pregnancy outcome in cycles where pregnancy in the initial 
fresh cycle was also achieved [2004-2014] 
 
2) The Effect of storage device on Pregnancy outcomes (Survival, Biochemical 
Pregnancy and Clinical Pregnancy rates) [Vitriplug vs. Cryotop®] 
3) The Effect of oocyte age on Pregnancy outcomes [Cryotop® data only] 
4) The Effect of day of vitrification on Pregnancy outcomes [Cryotop® data only] 
5) The effect of the number of embryos transferred on Pregnancy outcomes [Cryotop® 
data only] 
6) The effect of using donor oocytes on Pregnancy outcomes  
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4.1.2. Statistical Analysis 
 
Professor Martin Kidd, Director of the Centre for Statistical Consultation (CSC) at the 
University of Stellenbosch analysed the retrospective data. STATISTICA 12 (ANOVA) was 
used to generate the results described in Chapter 5. The results are expressed as the mean ± 
standard deviation of the mean and significance is accepted at p≤0.05.  
4.1.2.1. Definitions 
 
Survival Rates: (no. of embryos survived/no. of embryos warmed*100) 
Biochemical Pregnancy Rates: (no. of cycles with positive βhCG/total no. of embryo transfer 
cycles*100) 
Biochemical Pregnancy: A cycle recording a positive quantitative βhCG recording 
[Addendum 17]. 
Clinical Pregnancy Rate: (no of cycles with clinical pregnancy/total no. of embryo transfer 
cycles*100) 
Clinical Pregnancy: A clinical pregnancy is defined as a positive sonographic fetal 
heart beat at 7 weeks gestation. 
Good quality Embryo Classification: (Veeck, 2003) 
 Day 5: minimum expansion embryo grading of 1; no C grading for ICM or TE 
 Day 6: embryo expansion grading of 2-3; no C grading for ICM or TE 
Day 7: minimum embryo expansion grading of 3; no C grading for ICM or TE 
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Chapter Five 
 Results 
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Data recorded in patient files obtained from Drs Aevitas Institute for Reproductive Medicine 
over the period of 2004-2014 was collated and analysed retrospectively in this study. All 
patients enrolled at the Institute undergoing an FET cycle were considered for the study. 
Those patients that did not receive an embryo transfer were excluded from the outcomes 
analysis of the study. Cycles with missing data had to be excluded from the study for an 
accurate comparison to be conducted. As a result, 231 cycles were eligible for statistical 
analysis. Over the years, recording of data and outcomes has become more formalised, 
resulting in the later years having a greater representation in the results. Positive Biochemical 
Pregnancies are defined with an βhCG >10 and a proceeding βhCG of at least double the 
original value. Clinical Pregnancies were only calculated for the years 2013-2014, again due 
to the more recent implementation of a more structured recording system. Positive Clinical 
Pregnancies are defined as the presence of at least one fetal heart at 7 weeks. For the period 
2004-2008 the Vitriplug® storage device was used which was then replaced by the Cryotop® 
device for the remainder of the study. No of obs indicates the Number of Observations. 
STATISTICA 12 (ANOVA) was used to analyze the results of the study, which are presented 
in Figures 5.1-5.24 and included: 
1) Descriptive Statistics 
2) The Effect of storage device on Pregnancy outcomes (Survival, Biochemical Pregnancy 
and Clinical Pregnancy rates) [Vitriplug vs. Cryotop®] 
3) The Effect of oocyte age on Pregnancy outcomes  [Cryotop®  data only] 
4) The Effect of day of vitrification on Pregnancy outcomes [Cryotop®  data only] 
5) The effect of the number of embryos transferred on Pregnancy outcomes [Cryotop®  
data only] 
6) The effect of using donor oocytes on Pregnancy outcomes  
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5.1. Descriptive data  
 
The total number of vitrification cycles (all patient cycles that had embryos vitrified) for the 
study period was 818. 417 cycles, of which, only underwent vitrification whilst the remaining 
401 cycles underwent both vitrification and warming. 1817 blastocysts were vitrified and 856 
blastocysts were warmed for embryo transfer.  
As mentioned previously, FET cycles with no embryo transfer were excluded from the study, 
as well as those cycles in which there was missing data. Consequently N=231 cycles were 
evaluated and the results reflect the vitrification/warming programme and thus the pregnancy 
outcomes of the aforementioned cycles.  
The overall survival rate for those cycles that underwent embryo transfer was calculated at 
86.8%.  
The Descriptive Data is displayed in Figures 5.1-5.11.  
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Figure 5.1 shows the incidence of 100% survival (the survival of all embryos in each 
respective transfer cycle) as well as the incidence of <100% survival. 78% [181/231] of the 
warming cycles had a survival rate of 100% while 22% [50/231] had a <100% survival.  
 
 
Figure 5.1: Incidence of survival rates [2004-2014] after warming of vitrified blastocysts 
 
No of obs = Number of vitirifcation/warming cycles 
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Figure 5.2 shows that, overall, a biochemical pregnancy rate of 35% [80/231] was observed. 
Complete data to calculate clinical pregnancy for 2004-2012 was unavailable. 
 
 
Figure 5.2: Biochemical Pregnancy Rates [2004-2014] (+ βHCG/ itirifcation/warming 
embryo transfer cycle) 
 
No of obs = Number of vitirifcation/warming cycles 
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Figure 5.3 shows that the Clinical Pregnancy rate for the period 2013-2014 was 47% [18/42].  
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Figure 5.3: Clinical Pregnancy Rates [2013-2014] (fetal heart/ itirifcation/warming embryo 
transfer cycle) 
. No of obs = Number of vitirifcation/warming cycles 
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Figure 5.4 shows that median and mean female (oocyte) age was calculated to be 31±5.3 
years. The average age range was 20.0 – 46.0 years. [Number of cycles (N) = 231] 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 5.4: Incidence of female age (oocyte age in years) in vitrification/warming cycles [2004-2014] 
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Figure 5.5 shows that 15% [35/231] of the warming cycles had embryos frozen on Day 5, 
77% [177/231] on Day 6 and 8% [19/231] on Day 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Day of vitrification  
 
Figure 5.5: Incidence of vitrification in warming cycles on different days of blastocyst development 
[2004-2014] 
 
No of obs = Number of vitirifcation/warming cycles 
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Figure 5.6 shows that 27% [63/231] of the warming cycles made use of donor eggs.  
 
  
Figure 5.6: Incidence of Donor Oocyte vitrification cycles [2004-2014] 
 
No of obs = Number of vitirifcation/warming cycles 
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Figure 5.7 shows that in 37% [86/231] of the warming cycles only 1 embryo transferred, 
while in 48% [111/231] cycles 2 embryos were transferred, in 14% [32/231] 3 embryos were 
transferred and in only 1% [2/231] 4 embryos were transferred. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Number of embryos transferred/cycle [2004-2014] 
 
No of obs = Number of vitirifcation/warming cycles 
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In each vitrification/warming cycle a total of either 1, 2, 3 or 4 embryos were vitrified 
respectively. Figure 5.8 shows that in 37% [85/231] of the cycles none of the embryos 
available to be vitrified were considered to be of good quality. 39% [89/231] of the cycles 
had only 1 embryo classified has good quality, 19% [43/231] had 2 good quality embryos, 
5% [12/231] had 3 good quality embryos and only 1% [2/231] of the cycles had all four 
embryos transferred classified as good quality. 
 
 
Figure 5.8: Incidence of Good Quality Embryos before Vitrification [2004-2014] 
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Consistent with results from Figure 5.8, Figure 5.9 shows the incidence of good quality 
embryos in each cycle post warming.  In 41% [95/231] of the warming cycles none of the 
embryos were considered to be of good quality. 42% [96/231] of the cycles had only 1 
embryo classified has good quality, 16% [37/231] had 2 good quality embryos, 1% [2/231] 
had 3 good quality embryos and only 1 of the cycles had all four embryos transferred 
classified as good quality. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Incidence of Good Quality Embryos post Warming [2004-2014] 
 
No of obs = Number of vitirifcation/warming cycles 
 
An increased percentage of good quality embryos available for transfer was associated 
positively (but not significantly) with an increased biochemical pregnancy rate (Fishers Exact 
Test, one tailed, p=0.17).  Good quality embryos prior to vitrification were also confirmed as 
having better survival rates post warming (p=0.17), although this was not statistically 
significant.  
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Figure 5.10 shows that 16% [38/231] of the warming cycles also had previous fresh cycle 
pregnancies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Incidence of Fresh Pregnancy Cycles in patients with frozen embryo transfers  
 [2004-2014] 
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Figure 5.11 shows that in the case of a fresh pregnancy where supernumerary embryos were 
vitrified, 41% [14/34] of the cycles went on to have positive pregnancy in subsequent FET 
cycles. In those cycles with no previous fresh cycle pregnancy, 37% [64/231] went on to have 
a positive pregnancy outcome in subsequent FET cycles. This, however, was non-significant 
(Fishers Exact Test, one tailed, p=0.39124).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: The incidence of FET pregnancy outcome in cycles where pregnancy in the initial fresh 
cycle was also obtained [2014-2014] 
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5.2. The Effect of storage device on Pregnancy outcomes [Vitriplug® vs. 
Cryotop®] 
 
The number of warming cycles analysed making use of the Vitriplug® device were 
significantly lower [n=24] than those using the Cryoptop® device [n =207]. This is due to the 
lower number of FET cycles being performed in the years before the Vitriplug® was replaced 
by the Cryoptop® as well as being due to the exclusion data.  
The mean female ages (oocyte age) were 31.0±4.54 and 30.9±5.4 for the Cryotop® and 
Vitriplug® devices respectively. 
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It can be seen in Figure 5.12 that 80% [166/201] of the warming cycles vitrified with the 
Cryotop® device were shown to have 100% survival of embryos warmed per cycle. Only 
63% [15/24] of those vitrified using the Vitriplug® device had a 100% survival rate. The 
fishers exact test found this to be significant at p=0.047, therefore the Cryotop® device 
had significantly better survival rates than the Vitriplug® device. 91.7% 166/181] of 
100% survival in the total warming cycles was attributed to the Cryotop® device and 
8.28% [15/181] was attributed to the Vitriplug® respectively.   
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Figure 5.12: The effect of the storage device Cryotop® vs Vitriplug® on post warming survival 
rates [2014-2014] 
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This graph [Figure 5.13] shows that 38% [78/207] of the warming cycles where the 
Cryotop® device was used for vitrification were shown to have a positive βhCG. Only 8% 
[2/24] of cycles using the Vitriplug® device for vitrification had a positive βhCG. The 
Cryotop® device vitrification cycles resulted in a significantly higher biochemical pregnancy 
rate compared to that in the Vitriplug® device cycles (Fishers Exact Test, one tailed, 
p=0.0025). 97.5% [78/80] of the biochemical pregnancies in the total warming cycles was 
attributed to the Cryotop® device and 2.5% [2/80] was attributed to the Vitriplug® 
respectively.  
Figure 5.13: The effect of the storage device on biochemical pregnancy [2004-2014] 
N= No (Negative Biochemical Pregnancy) 
Y= Yes (Positive Clinical Pregnancy) 
      No of obs = Number of vitirifcation/warming cycles 
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5.3. The Effect of Female age (oocyte age) on Pregnancy outcomes (post 
warming Survival, Biochemical Pregnancy and Clinical Pregnancy rates) 
 
 
In Figure 5.14 (Box-and-Whisker plot) it is shown that there is a strong trend, however it is 
non-significant (p=0.23), towards a decreased female age (oocyte age) being associated with 
the 100% embryo post warming survival group (31.5914).  
[<100%:  n=50; +100%: n= 181]  
 
Figure 5.14: The effect of female age (oocyte age in years) on post warming embryo survival rates 
[2008-2014] 
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This Box-and-Whisker plot [Figure 5.15] shows that there is a strong trend (but not 
significant) towards a decreased female age (oocyte age = 30.4625) being associated with a 
positive biochemical pregnancy (Mann- Whitney u test, p=0.34).  
[not pregnant: n=128; pregnant n=78] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: The effect of female age (oocyte age in years) age on Biochemical Pregnancy Rates 
[2008-2014] 
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This Box-and-Whisker plot [Figure 5.16] shows that there was no effect of female age 
(oocyte age) on Clinical Pregnancy (p=0.90) between the 2 groups (30.75 vs 30.5556). 
[fetal heart present: n=18; fetal heart not present: n=20] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: The effect of female age (oocyte age in years) on Clinical Pregnancy Rates [2013-2014] 
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5.4. The Effect of day of vitrification on Pregnancy outcomes [Cryotop® data 
only] 
 
Figure 5.17 shows that 83% [24/29] of cycles having embryos vitrified on day 5 were 
associated with 100% survival while 79% [127/161] of the cycles with embryos vitrified 
on day 6 were associated with 100% survival. Fishers Exact Test (one tailed) reported this 
as being non-significant (p=0.42395), therefore the day of vitrification did not affect the 
survival outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17: The effect of Vitrification Day (Day 5 or 6) on post warming Survival Rates [2008-2014 
– Cryotop® data only] 
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Figure 5.18 shows that 48% [14/29] of the cycles with embryos vitrified on day 5 had 
biochemical pregnancies, while only 36% [58/161] of those with vitrification on day 6 had 
biochemical pregnancies. The day of vitrification did not have a significant effect on the 
pregnancy outcome, with a Fishers Exact Test (one tailed) reporting a p value of 0.14840.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18: The effect of Vitrification Day (Day 5 or 6) on Biochemical Pregnancy rate Rates (2008-
2014 – Cryotop® data only) 
 
N= No (Negative Biochemical Pregnancy) 
Y= Yes (Positive Biochemical Pregnancy) 
      No of obs = Number of vitirifcation/warming cycles 
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Figure 5.19 (2013-2014 data) shows that 57% [4/7] of the warming cycles with embryos 
vitrified on day 5 had clinical pregnancies, while only 45% [14/31] of those vitrified on day 6 
had clinical pregnancies. Again this was non-significant (Fishers Exact Test, one tailed, 
p=0.43735) indicating that the day of vitrification did not affect the clinical pregnancy 
outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19: The effect of Vitrification Day (Day 5 or 6) on Clinical Pregnancy [2013-2014] 
 
N= No (Negative Clinical Pregnancy) 
Y= Yes (Positive Clinical Pregnancy) 
No of obs = Number of vitirifcation/warming cycles 
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This Box-and-Whisker plot [Figure 5.20] shows that cycles having embryos vitrified on day 6 
were significantly associated with patients of a lower age (31) than those (32.97) having 
vitrification on day 5 (p=0.03). The more favourable outcomes associated with vitrifying on 
day 5 are therefore not associated with a decreased female age (p=0.38). 
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Figure 5.20: The association of female age (oocyte age in years) with the Day of Vitrification (day 5 
or 6) (2008-2014 – Cryotop® data only) 
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Figure 5.21 indicates that within each group (Day 5 or Day 6 of vitrification) there was a 
trend towards a decreased female (oocyte) age being associated with a biochemical 
pregnancy. This Box-and Whisker plot shows that despite the trend, the oocyte age played no 
significant role in effecting the success on each day of vitrification (p=0.972). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21: The effect of female age (oocyte age in years) on biochemical pregnancy rates specific to 
the Day of Vitrification (2008-2014 – Cryotop® data only) 
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5.5. The effect of the number of embryos transferred on pregnancy 
outcomes  
 
Figure 5.22 shows that as there was an increase in the number of embryos transferred 
in each cycle, so was there an increase in the incidence of a biochemical pregnancy. 
We can therefore say that the number of embryos transferred is significantly 
associated with an increase in biochemical pregnancy rates (Fishers Exact Test, one 
tailed, p=0.007). There was no correlation between the female age (oocyte age) and 
the number of embryos transferred (Pearsons Correlation Coefficient reported as R=-
0.08). 
 
 
 
 
 
 
 
 
 
Figure 5.22: The effect of the number of embryos transferred on biochemical pregnancy rates [2004-
2014] 
N= No (Negative Biochemical Pregnancy) 
Y= Yes (Positive Biochemical Pregnancy) 
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5.6. The effect of using donor oocytes on Pregnancy Outcomes 
 
Figure 5.23 shows that 82% [49/60] of the cycles using donated eggs had 100% survival 
when warmed. 80% [117/147] of the cycles not using donor oocytes reported 100% 
survival. Fishers Exact Test (one tailed) showed that the use of donor oocytes did not 
significantly affect the chance of 100% survival (p=0.44782).  
 
 
Figure 5.23:  The effect of donor oocytes on post warming survival [2004-2014 - Cryotop® only] 
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Figure 5.24 shows that Biochemical Pregnancies were observed in 40% [24/60] of the 
warming cycles using donor eggs. 37% [54/147] of the cycles not using donor eggs reported 
Biochemical Pregnancies. Fishers exact Test (one tailed) showed that the use of donor 
oocytes did not play a significant role on the pregnancy outcome (p=0.38720).   
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Figure 5.24:  The effect of donor oocytes on pregnancy [2004-2014 – Cryotop® only] 
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Chapter Six 
Discussion and Conclusion 
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6.1 Discussion 
 
The objective of this dissertation was to look at the possible factors that can optimize 
vitrification/warming protocols using an established vitrification programme in place at Drs 
Aevitas Institute for Reproductive Medicine. 
The main purpose of the vitrification program at Drs Aevitas Institute for Reproductive 
Medicine is for the management of supernumerary embryos. We can report that during 2013, 
for all age groups, the Clinical Pregnancy rate in fresh cycles was 42.4% [n=239/564] , which 
was slightly higher than the 40% [n=24/60] in frozen cycles. During 2014, again for all age 
groups, fresh cycles had a 35.8% (n=182/508) Clinical Pregnancy rate, which was marginally 
lower than the frozen cycles, which had a 36.5% [n=38/104) Clinical Pregnancy rate.  
There is, therefore, no difference associated between the outcomes of the fresh and frozen 
cycles, which is consistent with recent literature (Roy et al., 2014). It is then plausible to state 
that there is a successful FET programme in practice at Drs Aevitas Institute for Reproductive 
Medicine. 
As a result we wanted to analyse the outcomes, over a period of years, to determine which 
variables were involved.  
Another objective was to determine ways in which the programme could be improved and 
consequently, we researched and proposed future studies. 
To do this we designed a Retrospective Study to allow for data collection, and the analysis 
thereof, over the period of years dating 2004-2014. We have also designed a Prospective 
Study, which was carefully constructed after a thorough literature survey [Chapter Two] was 
conducted to address the continual need for improving outcomes in any Assisted 
Reproductive Technology programme. 
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Our study had limited numbers due to exclusion factors, and as a result we decided to 
concentrate on the vitrification/warming cycles as our primary objective was to analyse the 
outcomes. The exclusion factors included patient cycles where information was missing. This 
was advised by the statistician, to allow for a more precise and accurate comparison between 
all varying categories. As previously mentioned, over the years the recording of data and 
outcomes have become more formalised, resulting in the later years having a greater 
representation in the results. This representation is also due to the increase in the number of 
FET cycles performed in more recent years. Clinical Pregnancies were only calculated for the 
years 2013-2014, again due to the more recent implementation of a more structured recording 
system. 
This study was also initially proposed including a Prospective Study that is divided into two 
phases. Due to a stipulation by The Health Research and Ethics Committee of the University 
of Stellenbosch, approval from the Minister of Health had to be obtained [2012 Amendment 
to the NATIONAL HEALTH ACT 61 OF 2003, Chapter 8, Section 57(4)] before continuing 
with the study. As a result of the novel process that it involves, and therefore the implications 
that it had on our time restraint, the prospective study could not be carried out yet and we 
have included the proposal as part of proposed Future Studies [Chapter Seven].   
 
As the outcomes were the main focus of the study, emphasis was placed on the effect of 
female age (oocyte age); the vitrification carrier device; the day of vitrification; and the 
number of embryos transferred. We found that the carrier device as well as the number of 
embryos transferred had a significant effect on the outcomes. 
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6.1.2 The effect of female age (oocyte age) on vitrification/warming cycle 
outcomes 
 
In 1994, Navot et al. conducted a study to evaluate the contribution of the uterus to age-
related reproductive failure in women. To do this they harvested oocytes from a single donor 
during a specific cycle and distributed them evenly between young recipients and old 
recipients. The two recipient groups were classified according to female age, specifically 
35.8 +/- 3.1 years and 44.0 +/- 3.1 years respectively. They found that 21.6% of the Clinical 
Pregnancies achieved were observed in the young recipients and 23.5% of Clinical 
Pregnancies were attributed to the older recipients. This indicates that it is the oocyte [donor] 
age and not the recipient female age that plays a role in the capacity to conceive and carry a 
conception to term. This was supported by Abdalla et al. (1997) who stated that the decline in 
fecundity with age cannot be explained by uterine factors alone. In 63 of the 231 [63/231] of 
the analyzed cycles donor oocytes were involved. In our study we therefore considered 
female age to be the age of the oocyte source instead of the recipient age of those embryos 
selected to by cryopreservation. 
 
Although it is widely accepted that a reduced female age (oocyte age) would result in more 
favourable pregnancy outcomes (Piette et al., 1990; Van Noord-Zaadstra et al., 1991; Gilbert 
et al., 1999), our results only found strong trends towards this association rather than a 
significantly significant association. A reduced female age (ooctye age) was associated with 
the 100% post warming survival group with a P value of 0.23, and again the reduced female 
age (ooctye age) was associated with a positive biochemical pregnancy with a P value of 
0.34.  
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The Clinical Pregnancies calculated for the period 2013-2014 showed no significant 
difference between positive and negative resultant Clinical Pregnancies (p=0.90). It is, 
however, important to note that the mean age of the entire sample was 30.5 ± 4.6 years. 
Those patients with a clinical pregnancy had a mean age of 30.5 ± 3.8 years and patients 
without a clinical pregnancy had a mean age of 30.75 ± 5.2 years. From the start, however, 
there is no significant difference in the age range between the pregnant and non-pregnant 
groups. 
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6.1.3 The effect of the day of vitrification on vitrification/warming cycle 
outcomes 
 
As with female age (ooctye age) only strong trends were identified to indicate that the day of 
vitrification (day 5 or 6) played a role in the vitrification outcomes. This is evident with 
respect to the post warming survival as well as the biochemical and clinical pregnancies: 
When clinical pregnancies from day 5 vitrified blastocysts were compared to those that 
resulted from Day 6 vitrified blastocysts , the outcome of the Day 5 group was superior but 
not significantly so (83% vs 79% respectively). 
Biochemical pregnancies were shown to be unaffected by the day of vitrification (day 5 or 6) 
with observed rates of only 48% and 36% respectively. 
When clinical pregnancies observed on day 5 were compared to those clinical pregnancies 
resulting from day 6 vitrification, day 5 resulted in a higher rates, however, this too was non-
significant. 
The data showed that there was a significant association between patients of reduced female 
age (oocyte age) and vitrification on day 6 (p=0.03). This indicates that the favourable 
outcomes seen in those patients having embryos vitrified on day 5, could not be attributed to 
female age. 
From the retrospective data we calculated that 15% [35/231] of the vitrification/warming 
cycles had embryos frozen on day 5, while 77% [177/231] of vitrification/warming cycles 
had embryos vitrified on day 6.  
Vitrification on Day 5 was therefore shown to be more favourable, however, non-
significantly so.  Liebermann and Tucker (2005) as well as Sunkara et al. (2010) showed that 
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Day 5 vitrification had higher success rates, although other studies present inconsistent 
results (Liebermann and Tucker, 2006; Richter et al., 2006; Shapiro et al., 2008). 
It has to be emphasized however that, at Drs Aevitas Institute for Reproductive Medicine, day 
6 vitrification mainly takes place when the embryo grading on day 5 is not regarded as 
optimal (Addendum 4). The embryos are left to develop another 24hours to facilitate a more 
efficient selection process.  The majority of blastocysts vitrified on day 6 may therefore have 
reduced potential. This is different from a situation where day 6 vitrification takes place 
regardless of the quality of the embryo on day 5. This may be an explanation for our results. 
It also has to be noted that in practice, the laboratory personnel, in conjunction with the 
fertility specialist, make the final decision as to which day the embryos are vitrified. It is also 
common practice to delay vitrification to day 6 if it is thought that the blastocysts may 
develop further to better quality embryo a day later. This could account for the discrepancy in 
our results, where high percentages of embryos were considered to be poor quality according 
to the strict grading, however they underwent vitrification. 
It is important to note that, for example, a compact (or morula) stage embryo on day 5 is 
classified as poor quality (Veeck, 2003), however they have been shown to produce 
pregnancies in our clinic and it often also vitrified. This suggests that embryos graded as poor 
quality do not necessarily effect the pregnancy outcomes.  
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6.1.4. The effect of the storage device on vitrification/warming cycle outcomes 
 
The Vitriplug® vitrification cycle numbers are significantly lower than the Cryotop® 
numbers due to the aforementioned exclusion criteria as well as a reduced number of FET 
cycles being performed over the period of 2004-2008 when this storage device was used. 
It is important to note that the culture conditions were consistent over the 10 year period. The 
same dishes as well as culture medium were used, with the same culture conditions 
subsequently being followed throughout. 
The low sample number makes it difficult to accurately compare the two groups, however, 
significantly higher survival (p=0.047) and pregnancy rates (p=0.0025) were reported in the 
cycles using the Cryotop® device. The mean female ages (oocyte ages) were 30.9 (SD=5.4) 
and 31.0 (SD=4.54) for the Vitriplug® and Cryotop® devices respectively. This indicates 
that the difference in pregnancy outcomes could not be associated to female age (oocyte age) 
and therefore is due to the device itself.  
Better results with the Cryotop® device were to be expected as it was designed with the 
purpose of, and later confirmed, to improve the success rates of vitrification (Vajta and 
Kuwayama, 2006; Kuwayama, 2007; Vanderzwalmen et al., 2007). The improved outcomes 
could also be attributed to improved technique and the technician skills. The construction of 
the Vitriplug® device meant that a larger volume of liquid surrounded the embryo. It was 
later shown that minimal surrounding liquid is essential to the successful vitrification process 
(Vanderzwalmen et al., 2007), which also requires excellent technical skill. The Cryotop® 
device, being much smaller in construction, ensures that a smaller volume of liquid surrounds 
the embryo (Vajta and Kuwayama, 2006; Vanderzwalmen et al., 2007). Consequently higher 
cooling and warming rates can be achieved, which is essential for success in the vitrification 
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process.  With the evidently higher success rates depicted in our results, we too can confirm 
this phenomenon along in conjunction with the literature.  
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6.1.5. The effect of the number of embryos transferred on vitrification/warming 
cycle outcomes 
 
The data shows that an increase in the number of embryos transferred had a positive 
association with an increased incidence of a biochemical pregnancy (p=0.007).  
The American Society for Reproductive Medicine concluded that there was no difference 
between the pregnancy rates and live birth rates of single embryo transfers (SET) and double 
embryo transfers (DET). They also noted that SET was a more viable option for good 
prognosis patients (<35 years) than using selective methods for the most optimal embryo for 
transfer, and therefore confirming this exact guideline proposed by the ASRM in 2009. 
Our results, however, are consistent with Jones et al. (1998b) who reported that, in their 
study, the number of embryos transferred had a significant effect on clinical pregnancy. A 
greater chance of a clinical pregnancy was associated with an increase in the number of 
embryos transferred. Le Lannou et al. (2006) also showed that the pregnancy rate was 27.6% 
in single embryo transfers and 36.9% in double embryo transfers in fresh cycles. Single 
embryo transfer pregnancy was significantly lower (p<0.05) and was consistent with 
pregnancy rates of 14.4% and 23.5% in frozen embryo transfers respectively (Le Lannou et 
al., 2006). It is important to note that 8 cell embryos were transferred in this study. In a 
Cochrane Review Summary conducted by Pandian et al. (2014) SET was associated with a 
lower live birth rate than DET in fresh cycles. Berin et al. (2011), however, compared SET 
and DET of frozen blastocysts transfers. Clinical pregnancy rates (50.4% vs. 34.7%), live 
birth rates (45.8% vs. 30.6%), and twin live birth rates (19.3% vs. 0) were significantly 
higher in the DET versus SET group respectively (p < 0.05). This too is consistent with our 
results.  
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6.2. Conclusion 
 
We can therefore conclude that the Cryoptop® device (or similar, facilitating high cooling 
and warming rates) should be used in vitrification procedures, supporting the current 
implementation thereof at Drs Aevitas Institute for Reproductive Medicine. 
We can suggest that embryos, consistent with the literature, be vitrified on Day 5 for more 
favourable pregnancy outcomes – but that day 6 vitrified embryos also contributes 
significantly to the positive outcomes in our clinic and should always be considered. 
There are increasing amounts of Reproductive Institutions adopting SET approaches in both 
fresh and frozen cycles. From the data, and supporting literature previously mentioned (Jones 
et al., 1998b, Le Lannou et al., 2006, ASRM, 2012), we wouldn’t propose the 
implementation of SET into routine cycles for optimal pregnancy outcomes.    
When the total pregnancy outcomes at Drs Aevitas Institute for Reproductive Medicine for 
the period 2013-2014 were compared, it was evident that the pregnancy rate which resulted 
from FET cycles were higher than that of those that were achieved in fresh cycles. There is 
evidence to suggest that freezing all resulting embryos of sufficient quality in each respective 
cycle, for transfer at a later date, may be beneficial (Roque et al., 2013) 
To further optimize the outcomes of the vitrification/warming programme we researched 
possible techniques that could facilitate this process. Assisted Hatching was found to be 
beneficial in numerous failed fresh cycles (Chao et al., 1997; Das, 2006; Martins et al., 2011) 
as well as in -women of increased age (Das, 2006; Liebermann, 2010). 11.68% [27/231] of 
patients in our established vitrification/warming programme had an oocyte age ≥38 years 
indicating that this could be a viable option. 
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Chapter Two identified trends to show the benefit of AH in frozen warmed embryos as well, 
but emphasised that the number of studies, to date, are too small to viably and significantly be 
compared. To clarify whether AH on frozen warmed blastocysts is indeed beneficial we have 
designed a prospective study, in which this can be tested, which is proposed in Chapter Seven 
(Future Studies).  
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Chapter Seven 
 Future Studies 
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7.1. Introduction 
 
In order to confirm the benefit of AH in frozen warmed blastocysts, more evidence is 
required. We were able to identify trends in the Literature as well as in Chapter Two. This 
research encompasses varying types of Assisted Hatching performed at various embryo 
development stages, however, we have designed a Prospective Study to accurately test the 
hypothesis that Laser Assisted Hatching is beneficial in vitrified/warmed human blastocysts. 
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7.2. Prospective Study Phase I 
 
Title: 
Phase I: Prospective Study on Donated, Vitrified-Warmed Human Blastocysts 
 
The aim of this study will be to compare the hatching and survival outcomes in the control 
and LAH groups to determine whether LAH is either detrimental, has no impact, or is 
beneficial in donated, vitrified-warmed human blastocysts.  
The embryos are donated for research by patients who have already undergone treatment at 
the facility.  
The Materials and Methods described in this Chapter pertain to standard protocols and 
procedures that patients frequenting Drs Aevitas Institute for Reproductive Medicine undergo 
during Assisted Reproductive cycles. 
Detailed methodologies are presented as Addenda in Chapter Nine. 
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7.2.1. Methods 
 
7.2.1.1. Patients 
Standard IVF and ICSI, PICSI and IMSI patients with stored, vitrified blastocysts who have 
consented to donating their embryos for scientific research [Addendum 18] will be included 
in the study. 
 
7.2.1.2. Ovarian Stimulation and oocyte aspiration  
 
Different but standard, routine procedures were followed for ovarian stimulation. A routine 
oocyte aspiration protocol (using a sonar guided method) was followed [Addendum 7]. 
 
7.2.1.3. Semen preparation and insemination 
 
Standard procedures for semen production and preparation were followed. Both the swim up 
and gradient centrifugation preparation methods were done depending on the semen 
characteristics [Addenda 5 and 6]. 
Standard IVF and ICSI insemination procedures were followed [Addenda 8 and 9].  
 
7.2.1.4. Embryo culture and evaluation 
 
All embryos were cultured and graded using standard protocols used at Drs Aevitas Institute 
for Reproductive Medicine [Addendum 2]. Blastocysts were graded according to the Gardner 
and Schoolcraft [Addenda 3 and 4] grading method (Veeck, 2003).  
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7.2.1.5. Blastocyst Vitrification 
 
Supernumerary embryos/blastocysts of good quality after fresh embryo transfer were vitrified 
on day 5 or day 6 (and in some instances on day 7), following a modified protocol designed 
for Cryotop® (Kitzimato®) vitrification (Cobo et al., 2008) with accordance to the Ferti-
Pro® Vitri Freeze kit protocol [Addendum 10], and currently being used at Drs Aevitas 
Institute for Reproductive Medicine. 
 
7.2.1.6. Blastocyst Vitrification [Addendum 12] 
 
 Vitrification was performed at room temperature and it was therefore ensured that the 
heated stage was turned off. 
 Two pulled glass pipettes were made and used for embryo manipulation. 
 A coloured Cryotop® was chosen and labelled with the patient’s initials and surname, 
ID number and date of vitrification on alternating sides at the top of the Cryotop® 
using an IVF-safe permanent marker.  
 Blastocysts with an expansion grading of 2 or higher were collapsed using a 
collapsing dish and micromanipulation needles. Collapsing was done at 37°C in drops 
of flushing medium covered with oil on a heated stage [Addendum 13]. 
Note: it is not necessary to collapse a hatched or hatching blastocyst. 
 Vitrification media (Fertipro® “VitriFreeze”) was aliquotted into labelled Eppendorf 
tubes. 
1: VitriFreeze Pre-incubation medium (200µl per patient) 
2: VitriFreeze Freezing medium1 (100µl per patient) 
3: VitriFreeze Freezing medium2 (100µl per patient) 
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7.2.1.7. Blastocyst Warming [Addendum 14] 
 
The blastocysts were warmed, again according to the routine, standard protocol in accordance 
with the Ferti-Pro Vitri Warming kit protocol (Addendum 4) used at Drs Aevitas Institute for 
Reproductive Medicine.  
 Warming was performed on a heated stage measuring 37°C. 
 Warming medium was warmed a minimum of 1 hour before (or the day before) to 
ensure a temperature of 37°C. 
- VitriWarming 1 (1000µl per patient) 
- VitriWarming2 (200µl per patient) 
- VitriWarming3 (200µl per patient) 
- VitriWarming4 (200µl per patient) 
 A centre well dish was also incubated to 37°C in the same fashion. 
 Enough pulled pipettes were available for blastocyst manipulation. 
 
 
7.2.1.8. Laser Assisted Hatching on Donated Warmed Human Blastocysts [Addendum 
19] 
 
During a standard FET cycle, embryos are incubated for a minimum of three hours post 
warming before transfer. This allows for an accurate assessment of survival. In this 
experiment, the control embryos will be transferred to a NUNC dish for incubation in 
blastocyst medium, as described in the warming protocol [Addendum 14]. The embryos will 
be cultured for 24 hours at the standard conditions used in the ART laboratory. Both hatching 
and survival status, or more specifically whether or not the embryo has indeed survived or not 
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or hatched or not, will be noted after the 24 hour incubation period. Survival is defined as 
having fully expanded and is not yellow in colour or degenerate. 
Experiment embryos to undergo LAH should be transferred to flushing drops (SAGE Quinn’s 
Advantage ® Medium with HEPES + SAGE Quinn’s Advantage ® Human Serum Albumin) 
covered with oil and then moved to the microscope fitted with laser and heated stage. 
The laser method of assisted hatching will be performed on donated, vitrified blastocysts to 
ascertain hatching outcome and survival rates. The Vitrification files of the consenting 
patients will be collected and two groups will be identified. The two groups will be designed 
so that similar blastocyst qualities and development stages are represented equally in both 
groups.  
Group 2 (LAH) we will follow the procedure below: 
 During the last warming step of the warming protocol [Addendum 14] when 
blastocysts are in the 0.125M sucrose solution and still collapsed, blastocysts (in a 
HEPES buffered medium),  will be transferred to the microscope equipped with the 
laser already set up for the laser procedure. The microscope makes use of a Zona 
Laser Treatment System (ZLTS) from Hamilton Thorne Research (Beverly, MA) 
(Tinney et al., 2005).  
 All procedures will be done at 37ºC on heated stages. 
 The zona pellucida will be lasered according to the protocol described in Addendum 
19. In summary, 4-6 consecutive shots are fired to create an opening of roughly 1/8 of 
the circumference. This hole is created on the opposite to where the ICM is positioned 
to avoid any damage from occurring. 
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 Lasered blastocysts will then be transferred into the last medium of the warming kit 
and the rest of the procedure continued routinely [Addendum 14], cultured for 24 
hours and hatching and survival rate will be noted. 
7.2.1.9. Ethical Considerations  
 
 The LAH method is a well published and implemented method worldwide with no 
known negative effects (some studies indicated positive outcomes) 
 Consideration of the implications of the National Health Act with regards to research 
involving embryos: 
Phase I approval from the Minister of Health will be applied for once ethical 
approval from HREC of Stellenbosch University has been obtained. 
Participating patients will receive information and counselling before being 
included and will give informed consent [Addendum 18]. 
Each patient will be allocated a number, to which only laboratory personnel can 
associate a name. This will ensure anonymity and confidentiality in the results, as 
well as in the retrospective portion of the study.  
 
7.2.2. Statistical Analysis 
 
Professor Martin Kidd, Director of the Centre for Statistical Consultation (CSC) at the 
University of Stellenbosch will be approached to analyze the data.  
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7.3. Prospective Study Phase II 
 
Title: 
Phase III: Prospective Randomized Control Trial 
 
The aim of this study will be to compare the pregnancy outcomes in the control (non LAH) 
and LAH groups to determine whether LAH is beneficial in vitrified-warmed human 
blastocysts.  
All patients undergoing an FET cycle will be counselled and made aware of the benefits and 
implications associated with LAH. All consenting patients will then be randomized according 
to a table [Addendum 21] to determine which patients undergo LAH and those who do not. 
The Materials and Methods described in this Chapter pertain to standard protocols and 
procedures that patients frequenting Drs Aevitas Institute for Reproductive Medicine undergo 
during Assisted Reproductive cycles. 
Detailed methodologies are presented as Addenda in Chapter Nine. 
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7.3.1. Methods 
 
7.3.1.1. Patients 
 
Standard IVF and ICSI, PICSI and IMSI patients with stored, vitrified blastocysts who have 
consented to LAH [Addendum 20] will be considered for the study. Patients will be 
counselled extensively in the benefits and implications of LAH before consenting.  
 
7.3.1.2. Ovarian Stimulation and oocyte aspiration  
 
Different but standard, routine procedures were followed for ovarian stimulation. A routine 
oocyte aspiration protocol (using a sonar guided method) was followed [Addendum 7]. 
 
7.3.1.3. Semen preparation and insemination 
 
Standard procedures for semen production and preparation were followed. Both the swim up 
and gradient centrifugation preparation methods were done depending on the semen 
characteristics [Addenda 5 and 6]. 
Standard IVF and ICSI insemination procedures were followed [Addenda 8 and 9].  
 
7.3.1.4. Embryo culture and evaluation 
 
All embryos were cultured and graded using standard protocols used at Drs Aevitas Institute 
for Reproductive Medicine [Addendum 2]. Blastocysts were graded according to the Gardner 
and Schoolcraft [Addenda 3 and 4] grading method (Veeck, 2003).  
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7.3.1.5. Blastocyst Vitrification 
 
Supernumerary embryos/blastocysts of good quality after fresh embryo transfer were vitrified 
on day 5 or day 6 (and in some instances on day 7), following a modified protocol designed 
for Cryotop® (Kitzimato®) vitrification (Cobo et al., 2008) with accordance to the Ferti-
Pro® Vitri Freeze kit protocol [Addendum 10], and currently being used at Drs Aevitas 
Institute for Reproductive Medicine. 
 
7.3.1.6. Blastocyst Vitrification [Addendum 12] 
 
 Vitrification was performed at room temperature and it was therefore ensured that the 
heated stage was turned off. 
 Two pulled glass pipettes were made and used for embryo manipulation. 
 A coloured Cryotop® was chosen and labelled with the patient’s initials and surname, 
ID number and date of vitrification on alternating sides at the top of the Cryotop® 
using an IVF-safe permanent marker.  
 Blastocysts with an expansion grading of 2 or higher were collapsed using a 
collapsing dish and micromanipulation needles. Collapsing was done at 37°C in drops 
of flushing medium covered with oil on a heated stage [Addendum 13]. 
Note: it is not necessary to collapse a hatched or hatching blastocyst. 
 Vitrification media (Fertipro® “VitriFreeze”) was aliquotted into labelled Eppendorf 
tubes. 
1: VitriFreeze Pre-incubation medium (200µl per patient) 
2: VitriFreeze Freezing medium1 (100µl per patient) 
3: VitriFreeze Freezing medium2 (100µl per patient) 
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7.3.1.7. Blastocyst Warming [Addendum 14] 
 
The blastocysts were warmed, again according to the routine, standard protocol in accordance 
with the Ferti-Pro Vitri Warming kit protocol (Addendum 4) used at Drs Aevitas Institute for 
Reproductive Medicine.  
 Warming was performed on a heated stage measuring 37°C. 
 Warming medium was warmed a minimum of 1 hour before (or the day before) to 
ensure a temperature of 37°C. 
- VitriWarming 1 (1000µl per patient) 
- VitriWarming2 (200µl per patient) 
- VitriWarming3 (200µl per patient) 
- VitriWarming4 (200µl per patient) 
 A centre well dish was also incubated to 37°C in the same fashion. 
 Enough pulled pipettes were available for blastocyst manipulation. 
 
 
7.3.1.8. Laser Assisted Hatching on Consenting, Randomized Patients [Addendum 19] 
 
As with the experimental (LAH) embryos in Phase II, those patients whose embryos are 
randomly allocated to the LAH group, in this phase, will be transferred to a NUNC dish for 
incubation in blastocyst medium, as described in the warming protocol [Addendum 14].  
Embryos to undergo LAH should be transferred to flushing drops (SAGE Quinn’s Advantage 
® Medium with HEPES + SAGE Quinn’s Advantage ® Human Serum Albumin) covered 
with oil and then moved to the microscope fitted with laser and heated stage. 
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The laser method of AH will then be performed according to the protocol described in 
Addendum 19.  
The LAH embryos will follow the procedure below: 
 During the last warming step of the warming protocol [Addendum 14] when 
blastocysts are in the 0.125M sucrose solution and still collapsed, blastocysts (in a 
HEPES buffered medium),  will be transferred to the microscope equipped with the 
laser already set up for the laser procedure. The microscope makes use of a Zona 
Laser Treatment System (ZLTS) from Hamilton Thorne Research (Beverly, MA) 
(Tinney et al., 2005).  
 All procedures will be done at 37ºC on heated stages. 
 The zona pellucida will be lasered according to the protocol described in Addendum 
19. In summary, 4-6 consecutive shots are fired to create an opening of roughly 1/8 of 
the circumference. This hole is created on the opposite to where the ICM is positioned 
to avoid any damage from occurring. 
 Lasered blastocysts will then be transferred into the last medium of the warming kit 
and the rest of the procedure continued routinely [Addendum 14], and left to culture 
for 3 hours to ensure survival before ET.  
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
114 
 
7.3.1.9. Embryo Transfer [Addendum 16] 
 
A minimum incubation time of three hours post warming was utilized prior to blastocyst 
transfer. This allowed adequate time to ensure survival of the frozen/warmed blastocyst. 
A standardized blastocyst transfer method (using sonar guidance) will be performed. 
Blastocysts will be transferred after the patient has been instructed to present with a full 
bladder. 
7.3.1.10. Human Chorionic Gonadotropin (HCG) Levels 
 
A quantitative βHCG will performed to determine early pregnancy, which can be 
extrapolated to an implantation rate. Blood was drawn according to standard procedure 
[Addendum 17] using a Vacutainer © on days 10 and 14 following embryo transfer.  
 
7.3.1.11. Pregnancy 
 
Patients will be continuously monitored throughout their pregnancy to determine the 
outcome. 
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7.3.1.12. Ethical Considerations  
 
 The LAH method is a well published and implemented method worldwide with no 
known negative effects (some studies indicated positive outcomes) 
 Consideration of the implications of the National Health Act with regards to research 
involving embryos: 
Phase II approval from the Minister of Health will be applied for once ethical 
approval from HREC of Stellenbosch University has been obtained. 
Participating patients will receive information and counselling before being 
included and will give informed consent [Addendum 20]. 
Each patient will be allocated a number, to which only laboratory personnel can 
associate a name. This will ensure anonymity and confidentiality in the results, as 
well as in the retrospective portion of the study.  
 
 
7.3.2. Statistical Analysis 
 
Professor Martin Kidd, Director of the Centre for Statistical Consultation (CSC) at the 
University of Stellenbosch will be approached to analyze the data.   
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1) Ethical Approval from the HREC of the University of Stellenbosch  
 
Approval Notice  
New Application  
  15-Oct-2013  
WILSON-POE, Emma Josephine  
  
Ethics Reference #: S13/05/102  
Human Blastocyst vitrification: A retrospective review of outcomes in an 
assisted reproductive technology (ART) clinic (2004 - 2013).  
  
Dear Miss Emma WILSON-POE,  
  
The New Application received on 16-May-2013, was reviewed by Health Research Ethics 
Committee 2 via Committee Review procedures on 18-Sep-2013 and has been approved.   
Please note the following information about your approved research protocol:  
  
Protocol Approval Period: 18-Sep-2013 -18-Sep-2014  
  
Present Committee Members:  
Davids, Mertrude MA  
Fernandez, Pedro PW  
Kruger, Mariana M  
Bardien-Kruger, Soraya S  
Barsdorf, Nicola  
De Roubaix, Malcolm JAM  
Moller, Marlo M  
Engelbrecht, Susan S  
Willett, Derrick DWE  
Edwards, C E  
Rohland, Elvira EL  
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Botha, Matthys MH  
 Please remember to use your protocol number (S13/05/102) on any documents or correspondence with the HREC 
concerning your research protocol.  
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require 
further modifications, or monitor the conduct of your research and the consent process.  
 After Ethical Review:  
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the 
Committee before the year has expired. The Committee will then consider the continuation of the project for a further 
year (if necessary). Annually a number of projects may be selected randomly for an external audit.  
Translation of the consent document to the language applicable to the study participants should be submitted.  
 Federal Wide Assurance Number: 00001372  
Institutional Review Board (IRB) Number: IRB0005239  
 The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health 
research and the United States Code of  
Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by 
the Declaration of Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical 
Research: Principles Structures and Processes 2004 (Department of Health).  
  
Provincial and City of Cape Town Approval  
  
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant 
authorities (Western Cape Department of Health and/or City Health) to conduct the research as stated in the protocol. 
Contact persons are Ms Claudette Abrahams at Western Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 
483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel: +27 21 400 3981). Research that will 
be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics approval is 
required BEFORE approval can be obtained from these health authorities.  
 We wish you the best as you conduct your research.  
For standard HREC forms and documents please visit: www.sun.ac.za/rds  
 If you have any questions or need further assistance, please contact the HREC office at 0219389207.  
  
 
Sincerely,  
  
Mertrude Davids  
HREC Coordinator  
Health Research Ethics Committee 2  
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2) Embryo culture and pre-blastocyst grading used at Drs Aevitas Institute 
for Reproductive Medicine 
 
 Following oocyte aspiration and retrieval, and prior to insemination, the oocytes are 
denuded in those patients undergoing ICSI treatment [Addendum 9].  
 The oocytes are then cultured Quinn’s Advantage ® Protein Plus Fertilization 
Medium, which is covered by Sage ® Oil for Tissue Culture. Insemination then occur 
[Addenda 8 and 9].  
 Incubate overnight at 37°C, 5% CO2 
 Day 1: Fertilization Check 
(In the case of IVF patients the oocytes are cleaned using denuding pipettes and rinsed 
well [Addendum 8] before checking for fertilization.) 
Check for PN and PB number on the inverted microscope fitted with heated stage. 
(Take note whether PN numbers are abnormal at > or < 2, or any other anomalies). 
Fertilization is indicated by the presence of 2PN. Transfer to preincubated Quinn’s 
Advantage ® Protein Plus Cleavage Medium drops covered with Sage ® Oil for 
Tissue Culture in a greiner dish and incubate overnight at 37°C, 5% CO2 
 Embryos are graded according to the number of cells present and the quality thereof. 
A scale ranging from 1-5 is used to grade the quality. 1 being of worst quality and 5 
being of the best. Cells are ideally equal in size with no fragments. 
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Figure 9.1:4 cell stage embryo with quality grade of 5 
http://www.yaleobgyn.org/yfc/ourservices/invitro/development.aspx 
 
 
 
 
 
 
 
 
 
Figure 9.2: 7 cell stage embryo with quality grade of 5 
http://www.yaleobgyn.org/yfc/ourservices/invitro/development.aspx 
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 Day 2: 2-4 cell 
On day 2 the embryos should have cleaved to a 2-4 cell stage and are graded 
accordingly. Slow dividers are usually evident of genetic abnormalities. 
 Day 3: 6-8 cell 
By Day 3 the embryos should have cleaved to a 6-8 cell stage and are graded 
accordingly.  
 Day 4: The cells within the embryo continue to grow and begin to tightly align 
themselves against each other to form a compact ball of cells, known as a morula or 
compacting embryo. The cells are no longer distinguishable from each other. 
 
 
 
 
 
 
 
 
 
 
Figure 9.3: Compacting embryo/Morula 
http://www.yaleobgyn.org/yfc/ourservices/invitro/development.aspx 
 
 
 Day 5: Blastocyst Stage [Addenda 3 and 4] 
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3) Blastocyst Grading: Drs Aevitas Institute of Reproductive Medicine  
 
Blastocyst Grading 
Degree of Expansion and hatching status 
1 Early blastocyst, the blastocoel filling more than half the volume of conceptus, but no      
expansion in overall size as compared to early cleavage stage embryos 
2 Blastocyst, the blastocoel filling more than half of the volume of conceptus, with slight 
expansion in overall size and notable thinning of the zona pellucida. 
3 Full blastocyst, a blastocoel more than 50% of the conceptus volume and overall size fully 
enlarged with a very thin zona pellucida 
4 Hatching blastocyst, non-preimplantation genetic diagnosis. The trophectoderm has 
started to herniate 
5 Fully hatched blastocyst, non-preimplantation genetic diagnosis. Free blastocyst fully 
removed from the zona pellucida. 
6 Hatching or hatched blastocyst, preimplantation genetic diagnosis. 
 
Inner cell mass (ICM) grading 
A Tightly packed, compacted cells 
B Larger loose cells 
C No ICM distinguishable 
D Cells of ICM appear degenerative 
 
Trophectoderm grading 
A Many healthy cells forming a cohesive epithelium 
B Few, but healthy cells, large in size 
C Poor, very large or unevenly distributed cells, may appear as few cells squeezed to the side 
D Cells of the trophectoderm appear degenerative 
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4) Gardner and Schoolcraft Blastocyst Grading System (Veeck, 2003) 
 
Figure 9.4: Gardner and Schoolcraft Blastocyst Grading System (Veeck, 2003) 
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5) Swim Up Method for Semen Preparation 
 
MATERIALS: 
 Sperm Preparation Medium 
METHOD: 
Semen Collection and Analysis 
- Obtain semen sample by masturbation  
- Allow sample to liquefy for 20 minutes 
- Estimate the count, motility and forward progression of the sperm 
Semen Preparation 
1. Dilute 0.5-1ml semen with 2ml warm sperm preparation media 
2. Vortex and centrifuge the sample at 450g for 10 minutes 
3. Remove the supernatant and resuspend the pellet again in 2ml of warm sperm 
preparation medium.  
4. Vortex and centrifuge at 450g for 10 minutes  
5. Remove the supernatant and gently overlay 0.5ml of sperm preparation medium 
6. Place the tube at an angle in the incubator set to 37°C for 60 minutes 
7. After the 60 minutes, gently remove the 0.5 ml of sperm preparation medium and 
place in a clean tube 
8. Make a wet-preparation slide of the sample and assess as outlined by the WHO 
criteria (WHO, 2010) 
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6) Sil-Select Gradient Method for Semen Preparation 
 
MATERIALS 
- SilSelect Media (Fertipro, Beernem, Belgium) 
- Sperm Washing Medium (SAGE In-Vitro Fertilization Inc., Cooper Surgical 
Company, Trumball, CT) 
METHOD 
Semen collection and analysis 
- Obtain semen sample by masturbation into sterile plastic containers 
- Allow fresh sample to liquefy and prepare within one hour of ejaculation 
- Make a wet preparation of the sample and evaluate the count, motility and forward 
progression 
Gradient Preparation 
- Discontinuous density gradients can be prepared with either two or three layers 
2 layers: 90% and 45% SilSelect  
3 layers: 90%, 70% and 45% 
- To prepare the gradient, 1ml of the SilSelect dilution with the highest density (90%) is 
placed at the bottom of a sterile conical gradient tube 
- Gently overlay with an equal volume of 45% SilSelect if a two-layer gradient is 
required, or 70% and then 45% SilSelect when a three layer gradient is required 
- The gradient is left to equilibrate at 37°C 
- Gently layer the semen onto the prepared, warmed gradient 
- Centrifuge at 400g for 18 minutes 
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- Following centrifugation, carefully aspirate the supernatant from the meniscus down 
towards the 90% SilSelect layer using a small bore-holed pipette, such as a glass 
pipette. Gently aspirate the top third of the 90% SilSelect layer leaving behind the 
sperm pellet and those sperm cells that may still be suspended in the remaining 90% 
SilSelect 
- Using a new pipette, remove the pellet from the gradient tube and place into a sterile 
conical-bottom tube.  
- Resuspend the remaining 90% SilSelect media containing sperm with 0.3ml sperm 
preparation media and flush (by aspirating in and out) the area of the tube where the 
bottom layer of the gradient was to capture any sperm stuck to the sides of the tube 
- Remove the suspension and transfer into the clean tube where the sperm pellet was 
placed  
- Add 2ml of warm sperm preparation medium to the suspension to dilute out the 90% 
SilSelect  
- Centrifuge at 450g for 10 minutes 
- Remove the supernatant and resuspend the pellet again in 2ml of warm sperm 
preparation medium 
- Centrifuge at 450g for 10 minutes 
- Remove the supernatant and resuspend the pellet in 0.2ml of warm sperm preparation 
medium 
- Make a wet preparation slide of the sample and assess count motility and forward 
progression as outlined by the WHO criteria 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
148 
 
7) Oocyte Retrieval Protocol 
 
Oocyte Pickup 
-Follicular fluid is aspirated using a long 16 gauge aspiration needle into sterile tubes and 
sent through to the laboratory. 
-The fluid is poured into large petri dishes under the stereomicroscope fitted with a heated 
stage. 
-Follicular fluid must be examined immediately after follicular aspiration and not at 37°C for 
later examination because red and white blood cells tend to adhere strongly to the cumulus 
cells. 
-If the cumulus is heavily stained with blood then those areas of cumulus can be removed 
with sterile needles because it is well established that the blood interferes with the 
fertilization rate and subsequent embryo quality. 
-The oocyte-corona-complexes (OCC) are identified, graded (MI vs MII) and collected with a 
sterile, rounded, wide-bore glass pipette. 
-The OCC are transferred into test tubes (MI and MII) into approximately 2.0ml fresh, 
warmed flushing medium to wash them of excess blood. 
-The OCC are then transferred into Greiner dish with 2.0ml gassed fertilization medium at 
37°C and incubated until denuding or insemination time. 
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8) IVF Procedure used at Drs Aevitas Institute for Reproductive Medicine 
 
Semen Preparation 
- See Addenda 4 and 5 
Medium preparation 
- Medium is prepared the previous day in a CO2 incubator for equilibration  
Aspiration 
- Check suction pump (100-120mmHG) 
- Prepare glass polished pipettes for pick up 
- Place pick-up tubes in heated block 
- Hand theatre medium tube to sister when needed 
- Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large petri dish on a heated stage of a dissection microscope 
- Determine maturity (GV, MI, MII) 
- Put the complexes in the pick-up tubes (MI and MII separate) 
- When done, rinse all complexes in small petri dish with gassed fertilization medium – 
check number obtained 
- Transfer to 4 well NUNC dish with gassed fertilization medium – maturities separate 
and not more than 5 complexes per well 
- Incubate in the CO2 incubator until insemination 
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Insemination 
- Inseminate complexes with the correct number/volume of prepared sperm cells 
according to the sperm count after semen preparation 
- Do insemination ±40 hours post HCG administration if possible 
- Incubate overnight at 37°C, 5% CO2  
- The next morning, clean oocytes with denuding pipette ( Cook, Australia) and check 
for fertilization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
151 
 
9) ICSI Procedure used at Drs Aevitas Institute for Reproductive Medicine 
 
 
Prior to Injection 
 
Denuding of oocytes 
Cumulus cells are removed using SAGE ® hyaluronidase solution and fire drawn and 
polished glass Pasteur pipettes. 
Corona cells are then removed using denuding pipettes with a stripper pipette attached. 
 
Intracytoplasmic Sperm Injection 
 
The microinjection procedure is performed on an inverted microscope equipped with: 
1. A heated microscope stage (37°C) 
2. Two coarse and fine control manipulators 
3. Two micro injectors, one for the holding pipette and the other for the injection pipette. 
The holding pipette is inserted into the pipette holder and manually positioned so that the 
angled section is perpendicular to the microscope stage. The pipette is positioned using the 
coarse manipulators. The microinjection pipette is inserted into the pipette holder and 
manually positioned so that the angled section is at an angle approximately 20° to the 
microscope stage. The angel is to ensure that the tip of the microinjection needle will touch 
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the surface first. It must also be ensured that the two pipettes (holding and injection) move in 
line with each other. 
The microinjection dish is made according to the configuration of your microinjection system 
and the experience of the technician. The dish must, however, contain certain basic elements; 
an oocyte droplet (flushing medium), spermatozoa (in sperm prep medium) and a PVP 
droplet. 
The microinjection pipette is first carefully lowered into the clean PVP droplet. Before the 
manipulation of sperm is attempted PVP medium is repeatedly aspirated and expelled to coat 
the inside of the microinjection pipette. A large enough volume (for optimal control) of PVP 
is aspirated and the pipette is lifted and moved to the sperm storage droplet. 
Sperm selection and Immobilization 
The motile spermatozoa pipetted into the storage droplet (medium or PVP) swim to the outer 
perimeter of the droplet. When selecting a sperm cell preference is given to the sperm which 
appear morphologically normal and swim progressively forward. The motile sperm is 
aspirated into the injection pipette, the pipette is lifted and then moved to the clean PVP 
droplet. The pipette is lowered to just above the surface (in the PVP droplet), the sperm is 
slowly ejected moving up or down so that the sperms tail is transversely positioned to the 
pipette. The pipette tip is lowered onto the section of the tail just below the midpiece. The 
pressure and the movement of the microinjection needle on and over the sperm tail 
destabilizes the sperm membrane system and immobilizes the sperm. Destabilizing the sperm 
membrane before ICSI appears to be of crucial importance for decondensation of the sperm 
head and pronuclei formation. It must be ensured that the sperm is immotile before injection, 
as a motile sperm may cause structural damage within the oocyte ooplasma. The sperm is 
aspirated and ejected repeatedly to ensure that the sperm cell can be ejected during the 
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injection procedure. The selected immobilized sperm is aspirated tail first into the 
microinjection pipette. The microinjection pipette containing the sperm is lifted and moved to 
the oocyte droplet.  
 
Oocyte Microinjection 
An oocyte is added to each oocyte droplet in the dish. 
Using the microinjection pipette the oocyte is rotated to locate the polar body at the 12 
o’clock or 6 o’clock position. The holding pipette is lowered and the oocyte held by gentle 
suction. The microscope is focussed on the oocytes equatorial plane and the internal lumen of 
the holding pipette. The microinjection pipette is lowered into the same focus plane at the 3 
o’clock position. The plane of the microinjection pipette can be corrected by gently pushing 
on the ZP. The sperm is carefully brought forward to the point of the microinjection pipette 
and the pipette is pushed carefully though the ZP and through the oolemma and ooplamsa. 
The successful penetration of the oolemma is indicated by the ability to aspirate ooplamsa 
into the pipette. The ooplasma and sperm cell are then carefully ejected into the oocyte and 
the microinjection pipette is then withdrawn and the oocyte released from the holding pipette. 
The process of penetrating the oolemma and the aspiration of a small volume of ooplasma 
also helps to activate the oocyte which is essential for the normal process of fertilization to 
occur. Care must be taken not to eject a large volume of PVP medium into the oocyte, 
because this inevitably leads to oocyte degeneration. The whole procedure is repeated for all 
the oocytes in the microinjection dish. 
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10) FertiPro® VitriFreeze/VitriWarming Protocol 
 
VitriFreeze
TM
 
VitriWarming
TM 
Intended Use 
VitriFreeze
TM 
 and VitriWarming
TM 
are a set of ready-to-use media for vitrification and 
warming of human embryos. 
Background 
Vitrification which is preservation of cells at extremely low temperatures without ice crystal 
formation and can be more favourable than slow cooling (Kuleshova and Lopata, 2002). Due 
to variable results after application of slow-freezing methods for blastocysts, vitrification was 
introduced as an alternative approach. The success rates of vitrification have been increased 
with the use of ultra-rapid vitrification procedures. For several years, vitrification of 
blastocysts and embryos using different embryo carriers have resulted in many pregnancies. 
In order to accomplish aseptic vitrification of blastocysts, the HSV High security Vitrification 
Kit (Cryo Bio System) was developed (Vanderzwalmen et al., 2000). The tip of the HSV 
straw is designed to hold the blastocysts in a very small volume of vitrification solution 
allowing very fast cooling and warming rates as compared to those achieved by immersion of 
sealed 0.25ml plastic straws into liquid nitrogen. An alternative, aseptic method is now 
available in the shape of the VitriSafe straw (available from FertiPro N.V.). 
Composition 
VitriFreeze/Warming are DMSO/ethylene glycol based vitrification media that also contain 
PBS, sucrose, Ficoll and human serum albumin (10-20g/Liter). VitriFreeze/Warming do not 
contain antibiotics.  
Material Included with the Kit 
VitriFreeze
TM
 kit (VF_KIT1) 
 1 vial of VitrFreeze Pre-incubation medium (5ml) 
 1 vial of VitriFreeze Freezing medium 1 (1ml) 
 1 vial of VitriFreeze Freezing medium 2 (2ml) 
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VitriWarming
TM
 kit (VF_KIT1) 
 1 vial VitriWarming Warming Medium 1 (5ml) 
 1 vial VitriWarming Warming Medium 2 (1ml) 
 1 vial VitriWarming Warming Medium 3 (1ml) 
 1 vial VitriWarming Warming Medium 4 (1ml) 
The media should be used in the order displayed above. 
Material Not Included in the Kit 
 well dishes (egNunc 144 444) 
 freezing tank with liquid nitrogen 
 water bath (able to hold 37◦C ) 
 attenuated pipettes 
 forceps 
 vitrification device (HSV device, Cryo Bio System) 
 LAF-bench (ISO Class 5) 
 Microscope 
 Lab timer 
VitriFreeze/Warming and embryo culture 
VitriFreeze/Warming can be used in combination with FertiCult media (Flushing, IVF and 
G3) before freezing and after warming. 
Product Specifications 
 Chemical Composition 
 pH between 7,20-7,40 
 Osmolality 
VitriFreeze Pre-Incubation medium: 270-290 mOsm/kg 
VitriWarming Warming Medium 4: 270-290 mOsm/kg 
VitriWarming Warming Medium 1: 805-845 mOsm/kg 
VitriWarming Warming Medium 2: 535-565 mOsm/kg 
VitriWarming Warming Medium 3: 405-435 mOsm/kg 
 Sterility: SAL 10-3 
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 Endotoxins: <0,25 EU/ml 
 Mouse Embryo Assay (blastocysts after 96h) ≥ 80% 
 Use of PhEur or USP grade products if applicable 
 The certificate of analysis and MSDS are available upon request 
 
Pre-Use Checks 
 Do not use the product if it becomes discoloured, cloudy, or shows any evidence of 
microbial contamination 
 Do not use the product is seal of the container is opened or effect when the product is 
delivered. 
Storage Instructions 
 Store between 2-8◦C 
 Do not freeze before use 
 Keep away from sunlight 
 The products can be used safely us to 7 days after opening, when sterile conditions are 
maintained and the products are stored at 2-8◦C. 
 Do not use after expiry date 
 
Warnings and Precautions 
Standard measures to prevent infections resulting from the use of medicinal products 
prepared from human blood or plasma include selection of donors and screening of individual 
donations and plasma pools for specific markers. Despite this, when medicinal products 
prepared from human blood or plasma are administered, the possibility of transmitting 
infective agents cannot be totally excluded. This also applies to unknown or emerging viruses 
and other pathogens. There are no reports of proven virus transmissions with albumin 
manufactured to European Pharmacopoeia specifications by established processes. Therefore, 
handle all specimens as if capable of transmitting HIV or hepatitis. Always wear protective 
clothing when handling specimens. Always work under strict hygienic conditions (e.g. LAF-
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bench ISO Class 5) to avoid possible contamination. Only for intended use. The long term 
safety of embryo vitrification on children born following this procedure is unknown. 
Method 
Ensure all media are well mixed before use. We strongly advise to read through all the steps 
of the vitrification/warming procedure before starting the procedure. 
Preliminary Steps 
In a 4-well dish fill the first well with 300µl of Pre-Incubation medium, the second with 
Vitri-Freeze 2 solution. Next open as many HSV devices as will be required for the 
vitrification step, taking into account that 1 HSV device can hold up to two embryos. 
Conveniently place the separate parts of the HSV device on the work bench for easy access 
later in the procedure.  
Freezing Procedure 
Transfer the embryos from the blastocyst cell culture medium into each of the VitriFreeze 
solutions using the following scheme: 
Stage Pre-Incubation VitriFreeze 1 VitrFreeze 2 Temperature 
Early Blastocyst 
Morulae 
2’ 2’ 30” Room 
temperature 
Blastocyst – 
Expanded 
Blastocyst 
2’ 3’ 30” 37°C 
Blastocyst – 
expanded 
blastocyst and 
artificial 
shrinkage 
2’ 2’ 30” Room 
temperature 
 
*Before starting the vitrification procedure, in order to reduce the negative effect of the 
blastocoel, expanded blastocysts should be collapsed by reducing artificially with a glass 
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pipette the volume of the blastocoel (Vanderzwalmen et al., 2002; Son et al., 2003; Hiraoka 
2004). 
 
Vitrification 
1. Using an attenuated pipette or an equally suitable device, deposit maximum 2 
blastocysts in a volume of approximately 0.3µl of VitriFreeze2, in the gutter of the tip 
of the vitrification straw. 
2. Place the vitrification straw in the outer sheath and seal it as indicated in the 
instructions for use of the HSV device. 
3. Plunge the sealed device into the liquid nitrogen. 
 
Warming 
1. Remove vitrification straw from the outer sheath as indicated in the instructions for 
use of the HSV device. 
2. Immediately plunge the vitrification straw into pre-heated VitriWarming Warming 
medium 1 (37°C) and leave in warming 1 for 3 minutes. 
3. Transfer into VitriWarming Warming medium 2 (37°C) and leave in this medium for 
2 minutes. 
4. Transfer into VitriWarming Warming medium 3 (37°C) and leave in this medium for 
2 minutes. 
5. Finally transfer into VitriWarming Warming medium 4 (37°C) and wash for at least 1 
minute. 
6. Transfer into blastocyst culture medium for continued cell culture. 
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11) Vitrification Consent Forms used at Drs Aevitas Institute for 
Reproductive Medicine 
 
INSTITUTE FOR REPRODUCTIVE MEDICINE 
TYGERBERG & VINCENT PALLOTTI HOSPITALS 
 
 
 
VITRIFICATION OF HUMAN EMBRYOS 
INFORMATION & CONSENT 
 
 
 Vitrification is a process similar to freezing. 
 Vitrification is a standard and routine method used all over the world to successfully 
preserve and store human embryos and especially blastocyst stage embryos. 
 Only embryos/blastocysts of top quality can be vitrified and warmed (warmed) 
successfully. 
 Human embryos/blastocysts can be stored in vitrified state for a number of years. 
 Some embryos/ blastocysts can be affected by the vitrification-warming process and 
may therefore not survive and not be available for transfer.  
 A warmed embryo/blastocyst cannot be vitrified a second time. 
 The transfer of surviving, warmed embryos/blastocysts does NOT guarantee a 
successful pregnancy. 
 
We have implemented a vitrification program at our clinic and need your consent to 
treat your supernumerary embryos, should vitrification be possible.  
Please note that only if embryos are vitrified will a form with the results be posted to 
you.  
 
Please complete the following form. 
 
 
We,         (Husband/Partner)  [I.D. No.  
         ] 
and         (Wife/Partner) [I.D. No.           
] 
referred by        (Doctor), request Aevitas clinic to vitrify 
and store our embryos, according to the provisions stated below: 
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1. An initial fee for the vitrification procedure and an annual storage fee (pro 
rata) is payable to the AEVITAS clinic; 
 
2. The AEVITAS clinic must be informed of any changes in personal details 
(eg. postal address; telephone numbers). If patients cannot be contacted 
using the latest personal details on record after a period of 1 year, the stored 
embryos will be warmed. 
 
3. Failure to pay the annual fee within 1 year after the account has been issued, 
will result in the stored embryo/s being warmed. 
 
4. Embryos will be stored for a maximum period of 3 years (for non-pregnant 
cycles). Thereafter they will be warmed. 
 
5. Embryos will be stored for a maximum period of 5 years (for pregnant 
cycles). Thereafter they will be warmed. 
 
6. Vitrified – stored embryos must be warmed and/or transferred before a new 
stimulation and oocyte aspiration cycle will be attempted. 
 
 
 We understand that the vitrified-stored embryos may not survive the 
warming process in preparation for embryo transfer, and that surviving, 
transferred embryos might not result in a pregnancy. 
 
 We understand the necessity of selecting embryos of sufficient quality for 
vitrification and give the doctor and laboratory staff the authority to make 
this decision. 
 
 We acknowledge that if, at any time, we wish to have our vitrified embryo/s 
warmed, and we both must give written consent to the AEVITAS clinic by 
means of the form which is available from the clinic. 
 
 In the event of the death of one or both husband and wife, the stored 
embryos must be:  
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(Please mark and initial the selected option) 
In the event of wife’s / partner’s death: 
assigned to the care of my husband/partner  
husband’s / partner’s name:                                              I.D. No. 
Warmed (warmed)  
used for scientific research  
offered for donation to a couple  
 
In the event of husband’s / partner’s death: 
Assigned to the care of my wife/partner  
wife’s / partner’s name:                                              I.D. No. 
Warmed (warmed)  
used for scientific research  
offered for donation to a couple  
 
In the event of death of both husband & wife: 
Warmed and (warmed)  
used for scientific research  
offered for donation to a couple  
 
 
Signed at ……………………………… on the ………. day of ………..…………….. 20 …….. 
Husband      (print name) 
(signature) 
 
Wife       (print name) 
(signature) 
 
Witness      (print name) 
(signature) 
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INSTITUTE FOR REPRODUCTIVE MEDICINE 
TYGERBERG & VINCENT PALLOTTI HOSPITALS 
 
STORAGE OF / VITRIFIED EMBRYOS 
RESULT OF VITRIFICATION PROCESS 
 
 
 
Dear Mr & Mrs        Date ______________ 
 
Result of vitrification process 
 
 
Number of embryos vitrified Cell stage 
  
  
  
  
 
 
Signed at …………………………… on the ………. day of ………..…………….. 20 
…….. 
 
Laboratory technologist       
(signature)        (print name) 
 
 
Head clinical technologist       
(signature)        (print name) 
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INSTITUTE FOR REPRODUCTIVE MEDICINE 
TYGERBERG & VINCENT PALLOTTI HOSPITALS 
 
WARMING OF VITRIFIED EMBRYOS 
 
 
If you no longer wish to continue the storage of your vitrified embryo/s, please 
complete the following form and return it to the clinic.  
 
Please note that BOTH partners MUST sign this form before any embryos can and 
will be discarded. 
 
 
Date: 
 
We hereby request that our vitrified embryos should be warmed and discarded. 
 
 
HUSBAND / PARTNER 
 
Surname: 
 
First name(s): 
 
Identity number: 
 
Signature: 
 
 
 
WIFE / PARTNER 
 
Surname: 
 
First name(s): 
 
Identity number: 
 
Signature: 
 
 
 
Institute for Reproductive Medicine 
 
 Tygerberg Hospital, 3rd Floor, Green Avenue, Room 22. 
Tel: (021) 938 5173  Fax: (021) 933 3084 
 Vincent Pallotti Hospital, Alexander Road, Pinelands. 
Tel: (021) 531 6999  Fax: (021) 531 7919 
 
 PO Box 19058, Tygerberg, Cape Town, South Africa, 7505. 
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12) Modified Vitrification Procedure used at Drs Aevitas Institute for 
Reproductive Medicine 
Vitrification Procedure used for the outcomes in the retrospective study 
 Done at room temperature 
 In an ICSI dish make a large drop of VitrFreeze Pre-incubation medium and a small 
drop adjacent to it. 
 Using a pulled pipette place the embryos into the smaller drop of medium and start 
the countdown timer at 7 minutes.  
 Aspirate clean medium from the big drop and then transfer the embryos from the 
small drop to the surface of the big drop, allowing them to float down. 
 Fetch enough liquid nitrogen in a deep polystyrene container to cover the clearly 
labelled Cryotop® straws. 
 Plunge the Cryotop® cover straw into the liquid nitrogen. 
 When there are 30 seconds left on the timer make 2 drops as before with VitriFreeze 
Freezing medium 1.  
 Once the 7 minutes of equilibration are over transfer the blastocysts from VitrFreeze 
Pre-incubation medium to VitriFreeze Freezing medium 1 as described above. 
 The blastocysts remain in VitriFreeze Freezing medium 1 for 2 minutes. 
 Repeat the process of making drops with of VitriFreeze Freezing medium 2 and 
culture the embryos in this medium for 30 seconds. 
 When there are about 15 seconds left on the timer aspirate the blastocysts with as little 
medium as possible and pick up of the Cryotop® using your free hand. 
 Move the dish away and focus on the Cryotop® tip. Place the blastocysts [1, 2 or 3] 
onto the Cryotop® and aspirate as much surrounding medium as possible. Do not 
place more than three embryos on one straw. 
 Plunge the tip of the Cryotop® quickly into the liquid nitrogen, stirring it for 5 
seconds. 
 While working under the liquid nitrogen, replace the cover straw over the Cryotop® 
®. 
 Store the Cryotop® combination in a liquid nitrogen tank at -196°C. 
 Do all the necessary paperwork – note the storage place, the colour of the Cryotop® 
and the date of vitrification. 
 Make sure all consent forms are in order.    
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13) Collapsing Protocol used at Drs Aevitas Institute for Reproductive 
Medicine 
 
 Place a holding and collapsing pipette into the ICSI manipulators. 
 Place a single blastocyst [grade 2 and 3) into each collapsing droplet [oil covered 
HEPES buffered flushing medium – SAGE] in a small petri dish. 
 Place the dish on the heated stage and lower the collapsing needle into the flushing 
medium of the dish. Aspirate flushing medium into the needle and bring the meniscus 
into your field of view as to see where suction begins. 
 Gently aspirate the blastocyst onto the holding pipette ensuring that the inner cell 
mass (ICM) is at 9 o’clock position  
 Insert the collapsing needle into the embryo with a quick, piercing movement through 
the zona into the blastocoele and ensuring not to touch the opposite side of the 
trophectoderm. 
 Gently aspirate with the collapsing needle, watching the meniscus slowly moving 
upwards. Aspirate as much fluid as possible, moving the needle into the area of fluid. 
Take care not to aspirate the trophectoderm or the ICM. 
 Once complete, remove the collapsing needle and release the collapsed blastocyst. 
 Once all the blastocysts are collapsed move the dish to the cooled, room temperature 
stage of the dissecting microscope. 
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14) Modified Blastocyst Warming Procedure used at Drs Aevitas Institute 
for Reproductive Medicine 
 
Blastocyst warming procedure used for the retrospective study  
 Collect the patient’s Cryotop® straw from liquid nitrogen storage in a deep 
polystyrene container, ensuring that the straw is submerged at all times. 
 Bring all warming media to 37°C 
 Fill a centre well dish with VitriWarming Medium 1 and place on the heated stage 
under the microscope. 
 Whilst working under the liquid nitrogen, remove the Cryotop® straw cover. 
 Quickly transfer the tip of the Cryotop® loaded with embryos to the VitriWarming 
Medium 1 in the centre well dish. 
 Look under the microscope to ensure that the blastocysts are dislodged from the 
Cryotop® into the medium. 
 Start the countdown timer for 3 minutes. 
 When there are about 30 seconds left make a large drop of VitriWarming Medium 2 
in a small petri dish and a small drop adjacent to it. 
 Using a pulled glass pipette remove the blastocysts from the centre well dish into and 
place them into the smaller of the two drops. 
 Start the countdown timer for 2 minutes. 
 Aspirate clean medium from the big drop and then transfer the blastocysts from the 
small drop to the big drop.  
 Again, when there are about 30 seconds left, make drops for VitriWarming Medium 3 
as previously described for Medium 2. 
 Follow this same procedure for VitriWarming Medium 4 
 The blastocysts must incubate in Medium 4 for at least 1 minute. 
 Embryos should then be transferred into a NUNC® 4 well dish containing blastocyst 
medium to be incubated, and later checked for survival. 
 A minimum incubation time of 3 hours is required before embryo transfer can occur. 
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15) Vitriplug Method of Blastocyst Freezing and Warming 
 
  
MEDIUMS  
  
Product  Company  Cat. No  Tel/fax/email  
Dulbeccoss PBS  LSS (Invitrogen)  14040-083    
Ethylene glycol  Sigma  E 9129    
DMSO  Sigma  D 2650    
Ficoll 400  Sigma  F 8636    
Sucrose  Sigma  S 1888    
HSA  Cooper Surgical      
Filters 0.22µm  Sartorius  16534    
Hemistraws 
(VitriPlug)  
Astro Medtec  VIT 100  astromed@utanet.at  
Steel balls  Astro Medtec  VIT-B-100  astromed@utanet.at  
Sperm straw 133 mm  
0.5 ml  
Astro Medtec  CBS-
011455  
astromed@utanet.at  
Flexible 
 conventional 
straws 133 mm e  
CryoBioSystem  014103  bl@cryobiosystemimv.com  
CBS 0.3 ml straw  CryoBioSystem  CBS-
010288  
bl@cryobiosystemimv.com  
Liquid Nitrogen        
LN2 storage container        
Marker pen        
LN2  vitrification  
container  
    Peter Rowley  
Culture media  Cooper Surgical      
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Solutions  
Make up stock solutions  
 
Stock A  
5 ml DMSO  
6 ml Dulbeccos PBS  
      1.5 ml HSA (100 mg/ml)  
      
• Mix DMSO and PBS thoroughly FIRST  
• Then add HSA  
• Filter sterilize  
(can keep for 2 weeks at 4ºC)   
     
Stock B  
5 ml ethylene glycol [EG]  
6 ml Tobaccos PBS  
      1.5 ml HSA (100 mg /ml)  
  
• Mix thoroughly  
• Filter sterilize  
(can keep for 2 weeks at 4ºC)   
   
Stock C (20% HSA/PBS)  
     2 ml HSA  (100 mg/ ml)   
      8 ml PBS  
  
• Mix thoroughly  
• Filter sterilize  
(can keep for 2 weeks at 4ºC)   
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Equilibration medium (E Medium)  
  
       2 ml of A      
       2 ml of B      
       4 ml of C  
 Mix thoroughly  
(can keep for 2 weeks at 4ºC)   
 10% EG, 10% DMSO  
  
 Vitrification medium (V Medium)  
  
       3 ml of A      
       3 ml of B      
       1.53 g Sucrose  
       60 mg Ficoll 400  
 Mix thoroughly  
(can keep for 2 weeks at 4ºC)   
 20% EG, 20% DMSO, 25 µmol/L Ficoll, 0,75 mol/L sucrose  
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Method 
  
• Label VitriPlug  
• Prepare LN2  
• Prepare cover straw (CBS-010288)  
• Cut back part (± 2.5 cm)  
• Put Cover straw in LN2  
• Find a storing space for embryos  
• Fill out all appropriate forms  
  
  
 For all cell types:   
  
• Remove embryo from culture medium  
• Wash in 2 drops (50 µl) of PBS/HSA20 at 37ºC  
  
   
Then do vitrification for different embryo stages as follow:  
  
Embryo stage  E Medium  V Medium  Temperature  
Morula  and  Early  
blastocyst  
  
2 minutes  30 seconds  25ºC  [room  
temperature]  
Blastocyst  3 minutes  
  
  
30 seconds   37ºC  
Expanded blastocyst  
  
4 minutes  30 seconds  37ºC  
Collapsed  expanded  
blastocyst  
2 minutes  30 seconds  25ºC  [room  
temperature]  
Hatching/hatched  
blastocyst  
  
2 minutes   30 seconds  25ºC  [room  
temperature]  
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• Aspirate embryo with mouth pipette (maximum 2 embryos/ VitiPlug)  
• Place in small volume (0.1-0.3µl) onto the VitriPlug tip  
• Plunge tip into LN2 and move gently around for a few seconds  
• Keep under LN2 and insert into precooled cover straw (held with a metal pincette)  
• Plunge into LN2  
• Store securely in documented storage place (under LN2)  
 
  
   
WARMING METHOD  
  
To be done 24 hours before embryo transfer (ET)  
  
Solutions  
• 0.5 M sucrose in PBS/HSA20  
      
      1.71 g sucrose in10 ml PBS/HAS20  
  
• 0.25 M sucrose in PBS/HSA20  
      
      2 ml 0.5 M sucrose + 2 ml PBS/HSA20  
  
• 0.125 M sucrose in PBS/HSA20  
  
      1 ml 0.5 M sucrose + 1 ml PBS/HSA20  
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METHOD  
  
• Place ± 3 ml of the 0.5 M sucrose solution in a small petri dish at 37ºC   
• In a separate petri dish put 2 drops of 0.25 M, 0.125 M and PBS/HAS.  
• Remove VitriPlug from storage tank  
• Remove cover straw very carefully  
• Insert VitriPlug tip with embryos directly into the 3 ml 0.5M sucrose at 37ºC  
 Stir for a few seconds  
• Make sure embryo/s are dislodged from the VitriPlug tip and free-floating  
• Incubate the embryos for 2, 3 or 4 in minutes in the 0.5M sucrose solution the 
medium.  
• Transfer to the big drop of 0.25M sucrose at room temperature for 2 minutes (I 
minute in each drop)  
• Repeat for the 2 drops of 0.125 M sucrose (2 minutes/ room temperature)   
• Transfer to the PBS/HSA20 drops for 2 minutes at room temperature  
• Transfer now to culture medium drop under oil at 37ºC (for blastocyst – to 
blastocyst medium)  
• Incubate for 24 hours before transfer  
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16) Embryo Transfer Protocol used at Drs Aevitas Institute for Reproductive 
Medicine 
 
Embryo Transfer Protocol 
 Place 0.7ml of blastocyst medium into wells 2 and 4 of a 4-well NUNC® dish and 
incubate in a CO2 incubator for a minimum of 3 hours. 
 10 minutes before the transfer, place the selected embryos/blastocysts into well 4 of 
the NUNC® dish and return the dish back to the incubator. 
 Supply the doctor with speculum rinsing medium at 37°C 
 Once the doctor has positioned the speculum take the syringe and soft catheter from 
theatre and move through to the laboratory. 
 Remove the NUNC® dish from the incubator an start the timer (transfer should take 
no longer than 2 minutes) 
 Use the syringe to aspirate all the medium from well 2 of the NUNC®. 
 Hold the syringe upright (tip up), tap it so any air bubbles move to the top and expel 
the bubbles. 
 Attach the Efficiere Series catheter (Cooper surgical) to the syringe and expel all the 
medium in the syringe through the soft catheter back into well 2 in order to rinse and 
fill the soft catheter with medium. 
 Lift the top of the soft catheter out of the medium and aspirate a small air bubble at 
the tip of the catheter. 
 Place the tip of the catheter into well 4, away from the embryos and aspirate first, a 
small amount of medium, followed by the embryos and more medium (0.2ml in total). 
You must ensure to visualize the embryos entering the tip of the soft catheter. 
 Double check well 4 to make sure that all the embryos for transfer are no longer there. 
 Move through to theatre and carefully hand the soft catheter and syringe to the doctor. 
 Once the doctor has indicated that the catheter is in place  - as seen on the sonar image 
-  slowly push  in the syringe plunger in a controlled manner and thereby the medium 
containing the embryos into the uterus, trying to visualize the “bubble” of medium on 
the sonar image. 
 Hold the plunger of the syringe in for about 5 seconds before releasing it. 
 The timer can be stopped at this point. 
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 Take the catheter back to the laboratory once the doctor has removed it. 
 While holding the tip of the catheter over the overturned lid of the NUNC® dish, 
remove the syringe from the catheter in order for the remaining liquid to be expelled. 
Aspirate air into the syringe and reattach to the catheter in order to expel any further 
medium that has not flowed out of the catheter. 
 Under the microscope check the expelled medium to ensure that all embryos have 
been transferred successfully.  
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17) Protocol for obtaining Human Chorionic Gonadotropin (HCG) Levels 
 
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone comprising 2 subunits, 
namely alpha and beta, which are joined non covalently. The corpus luteum is responsible for 
the production of progesterone during the luteal phase of the menstrual cycle. In the absence 
of fertilization, the corpus luteum undergoes the degradation process known as luteolysis, 
and, as a consequence, progesterone levels decline (Richard et al., 2001). In the event of 
fertilization, the hormone hCG is secreted by the implanting embryo and interacts with the 
Leutenizing Hormone Choriogonadropin Receptor to maintain the corpus luteum and 
consequently secrete progesterone. The progesterone enriches the uterus with a thick lining of 
blood vessels and capillaries so that it is able to sustain the developing foetus. Due to its 
highly negative charge, hCG may repel the immune cells of the mother, protecting the fetus 
during the first trimester.  
Although the timing from fertilization to the initial appearance of hCG can differ between 
assisted and unassisted pregnancies, the amounts and rate of increase per day of hCG levels 
are similar (Lenton et al., 1982). Implantation in patients usually occurs within 10 days after 
embryo transfer (Liu et al., 1995) and is the day on which the first hCG measurement is 
obtained.  The maternal plasma levels of hCG continue to double about every 2 days in a 
normally developing intrauterine pregnancy (Seeber, 2006), and peak at 6–8 weeks after 
conception, when production of progesterone is taken over by the placenta (Braunstein, 
1996). Failed pregnancies have been correlated with a low amount of hCG (France et al., 
1996) and with a slow doubling time during pregnancy (Kratzer and Taylor., 1990). 
Comparisons show that hCG mean levels are several times higher in successful pregnancies 
than in unsuccessful pregnancies (Seeber, 2006; Bjerke et al., 1999). 
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The Vacutainer© needle has a sharp point at both ends, covered by a rubber sheath, with one 
end being shorter than the other. The long end of the needle (distal) is used for penetrating the 
vein, the shorter end (proximal) is used to pierce the rubber stopper of the vacuum tube. The 
sheath makes it possible to draw several tubes of blood by preventing leakage of blood as 
tubes are changed, which is called a multi-draw.  
As the name implies, there is a vacuum in the collection tube. The vein is punctured with the 
distal hypodermic needle and when the sheathed proximal needle pierces the color-coded 
rubber stopper, blood is sucked into the tube. That assumes that the distal end of the needle 
has successfully pierced the vein.  
A positive βhCG recording is considered to be when the first reading (day 10) is >10 and the 
second reading (day 14) is at least double the amount recorded in the first reading. A 
Biochemical Pregnancy is defined as a Positive βhCG reading. 
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18) Proposed Phase I Informed Consent 
 
   DRS AEVITAS  
VINCENT PALLOTTI HOSPITAL 
DONATION OF FROZEN EMBRYOS FOR RESEARCH 
   
If you no longer wish to continue the storage of your vitrified embryo/s and wish to donate 
them to the clinic for research, please complete the following form and return it to the clinic.   
 Please note that BOTH partners MUST sign this form before any embryos can be 
used.  
   
Date:  
 We hereby give permission that our embryos be used by Drs Aevitas clinic for research 
purposes. We understand that the embryos will not be used for cloning research nor will they 
be offered to other patients.  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Vincent Pallotti Hospital, Alexander Road, Pinelands. 
 Tel: (021) 531 6999  Fax: (021) 531 7919  
 PO Box 112, Howard Place, Cape Town, South Africa, 7450.  
WIFE / PARTNER  
  
Surname:  
  
First name(s):  
  
Identity number:  
  
Signature:  
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19) Protocol for Laser Assisted Hatching used at Drs Aevitas Institute for 
Reproductive Medicine 
 
Laser Procedure 
 Turn on heated stage, microscope light and computer 
 Slide laser box into microscope and let it “click” back into alignment 
 Open ZILOS programme on computer 
Laser Alignment 
 Put cover slip with black marker onto heated stage  
 Click on “Setup” and “Begin target alignment” 
 Click on “Fire” 
 Use the cursor to click on the centre of the fired circle which will appear in the black 
marker. This will move the red arrow to the centre of that circle. 
 Repeat roughly 3 times until the hole that is shot is always at the red arrow. 
 Click “Alignment OK” 
Performing Laser Assisted Hatching  
 Transfer one embryo into a small drop of flushing medium under oil. 
 Transfer dish to heated stage. 
 Find the embryos location by looking through the microscope eye pieces. 
 Centre embryo on screen 
 Take measurements and picture 1 
 Move embryo so that the area where you are going to laser is positioned under the red 
arrow. The ICM should be positioned on the opposite side of the embryo and a large 
perivitteline space is preferable. An eight of the circumference of the embryo is 
required to be lasered. 
 Take photograph2 
 Transfer the embryo back into the culture drop 
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20) Proposed Phase II Informed Consent 
 
INFORMATION AND CONSENT 
Human Blastocyst Vitrification: Optimizing outcomes in an Assisted Reproductive 
Technology (ART) programme 
Emma Wilson Poe (BSc Hons); Dr De Beer (PhD); Prof Kruger (MD, PhD, DSc) & Mr Greg Tinney (MSc) 
Dept of Obstetrics and Gynecology, Stellenbosch University/Dr Aevitas Fertility Clinic, Pinelands. 
 
Please read the following and feel free to ask any questions. Participation is entirely 
voluntary and you are free to decline to participate. If you say no, it will not affect your 
treatment negatively in any way whatsoever. You are also free to withdraw from the project 
at any point. 
To implant into the uterus the embryo must escape from its outer covering, the zona 
pellucida. Assisted hatching involves creating a hole in the zona pellucida to facilitate this 
natural hatching process while in vitro. Some studies have shown that laser assisted hatching 
(whereby the hole is created by use of a laser) on frozen-warmed embryos can POSSIBLY 
increase implantation, pregnancy and live birth rates after transfer of such embryos. There 
have been no reports of any adverse effects. We are investigating this practise in our clinic. 
The frozen embryos in storage will be warmed before transfer. Patients will be randomized 
into two groups: in one group the zona pellucida of all the warmed embryos will be treated 
with laser to make an opening; and in the other group it will not be done. In both groups 
warmed embryos will be transferred using the routine standard embryo transfer method of the 
Dr Aevitas Clinic. 
 
DECLARATION BY COUPLE: 
We        (wife/partner)[ID No:     ] 
      (husband/partner)[ID No.:   ] 
agree to take part in a project entitled Human Blastocyst Vitrification: Optimizing outcomes 
in an Assisted Reproductive Technology (ART) programme. 
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 We have read or have had read to us the information on the consent form and it is written 
in a language with which I am fluent and comfortable. 
 We have had a chance to ask questions and all my questions have been adequately 
answered. 
 We understand that taking part in this project is voluntary and I have not been 
pressurised to take part. 
 We may choose to leave the project at any time and will not be penalised or prejudiced in 
any way. 
 This procedure will be at no additional cost to the patient. 
 
 
    
Signatures of participants 
 
 
 
Signature of witness 
 
Signed at (place)       on (date)  /   / 2014. 
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21) Randomized Table for Patient Distribution in Randomized 
Control Trial  
    
Laser Assisted hatching – vitrified –warmed blastocysts 
                     NAAM                                              PR  
1 A   
2 A   
3 B   
4 B   
5 B   
6 A   
7 B   
8 A   
9 A   
10 A   
11 B   
12 B   
13 A   
14 A   
15 A   
16 B   
17 B   
18 A   
19 B   
20 B   
21 A   
22 B   
23 A   
24 A   
25 B   
A LAH  
B Control  
     PBS/HSA2
0 
E medium 
(100 µl) 
V
 µl) 
Name etc 0.25  M 
sucrose 
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